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Abstract
Statistical analyses and modeling have contributed greatly to our understanding of the pathogenesis
of HIV-1 infection; they also provide guidance for the treatment of AIDS patients and evaluation
of antiretroviral (ARV) therapies. Various statistical methods, nonlinear mixed-effects models in
particular, have been applied to model the CD4 and viral load trajectories. A common assumption in
these methods is all patients come from a homogeneous population following one mean trajectories.
This assumption unfortunately obscures important characteristic difference between subgroups of
patients whose response to treatment and whose disease trajectories are biologically different. It also
may lack the robustness against population heterogeneity resulting misleading or biased inference.
Finite mixture models, also known as latent class models, are commonly used to model non-
predetermined heterogeneity in a population; they provide an empirical representation of hetero-
geneity by grouping the population into a finite number of latent classes and modeling the popula-
tion through a mixture distribution. For each latent class, a finite mixture model allows individuals
in each class to vary around their own mean trajectory, instead of a common one shared by all
classes. Furthermore, a mixture model has ability to cluster and estimate class membership proba-
bilities at both population and individual levels. This important feature may help physicians to better
understand a particular patient disease progression and refine the therapeutical strategy in advance.
In this research, we developed mixture dynamic model and related Bayesian inferences via
Markov chain Monte Carlo (MCMC). One real data set from HIV/AIDS clinical management and
another from clinical trial were used to illustrate the proposed models and methods. This disserta-
tion explored three topics. First, we modeled the CD4 trajectories using a finite mixture model with
four distinct components of which the mean functions are designed based on Michaelis-Menten
function. Relevant covariates both baseline and time-varying were considered and model com-
parison and selection were based on such-criteria as Deviance Information Criteria (DIC). Class
vi
membership model was allowed to depend on covariates for prediction. Second, we explored dis-
ease status prediction HIV/AIDS using the latent class membership model. Third, we modeled viral
load trajectories using a finite mixture model with three components of which the mean functions
are designed based on published HIV dynamic systems. Although this research is motivated by
HIV/AIDS studies, the basic concepts and methods developed here have much broader applications
in management of other chronic diseases; they can also be applied to dynamic systems in other
fields. Implementation of our methods using the publicly-available WinBUGS package suggest that
our approach can be made quite accessible to practicing statisticians and data analysts.
vii
Chapter 1
Introduction
1.1 HIV/AIDS background
In 1981, doctors in Los Angeles, San Francisco, Atlanta and New York reported that a small num-
ber of homosexual men had been diagnosed with rare forms of Kaposi’s sarcoma and Pneumocystis
carinii pneumonia, which are generally found in people with seriously compromised immune sys-
tems. It became clear that an unknown disease, for which we did not know the mechanism, had
appeared. In September 1982, Centers for Disease Control and Prevention (CDC) used the term ac-
quired immune deficiency syndrome (AIDS) as an official diagnosis for this disease, characterized
by a severe impairment of the immune system.
Acquired immune deficiency syndrome (AIDS) is the final stage of human immunodeficiency
virus (HIV) infection. HIV infection is acquired primarily by unprotected sexual intercourse, ex-
posure to contaminated blood or plasma, or maternal-fetal transmission. The risk of transmission
after single encounter with an HIV source has been estimated to be 1 in 150 with needle sharing, 1
in 300 with occupational percutaneous exposure, 1 in 300-1000 with insertive vaginal intercourse,
and 1 in 3000 with insertive anal intercourse [1].
Since the beginning of the epidemic, almost 75 million people have been infected with the HIV
and about 36 million people have died of AIDS. By the end of 2012 (UNAIDS 2013), 35.3 mil-
lion people were living with HIV approximately. An estimated 0.8% of adults aged 1549 years
worldwide are living with HIV, although the burden of the epidemic continues to vary considerably
between countries and regions. Sub-Saharan Africa remains most severely affected, with nearly 1 in
every 20 adults living with HIV and accounting for 71% of the people living with HIV worldwide.
HIV belongs to a class of viruses known as retroviruses which use ribonucleic acid (RNA) to en-
code their genetic information. The RNA is translated into deoxyribonucleic acid (DNA) during its
life-cycle by a specific viral enzyme called reverse transcriptase. Viruses cannot grow or reproduce
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on their own so they must infect cells of a living organism in order to survive and make new copies.
Figure 1.: Diagram of HIV (from the website of US National Institute of Health).
Figure 1 shows the basic structure of HIV, which is roughly spherical and has a diameter of about
1/10,000 mm. It has a lipid membrane, which is the outer envelope of the virus and consists of two
layers of lipids. Different proteins are embedded in this viral envelope consisting of glycoprotein
(gp) 120, needed to attach the virion to the host cell, and transmembrane gp41, needed for the cell
fusion process. Between the envelope and core, there lie matrix proteins. The viral core contains
the viral capsule protein p24 which surrounds two single strands of RNA and the enzymes needed
for HIV replication, such as reverse transcriptase, protease, ribonuclease, and integrase. Nine virus
genes, including gag, pol and env, coded on one long stand of RNA are needed to make structural
proteins for new virus copies.
Figure 2 shows the six steps of the HIV infection and replication process. (i) By binding specific
receptors on the surface of a target cell, such as CD4 positive T cells (i.e., CD4 cells), macrophages
and microglial cells, HIV enters the host cells. The CD4 receptor is necessary but not sufficient to
permit virus entry. The secondary receptors are “chemokine receptors” that bind to chemokines and
are needed to facilitate the entering [2]. (ii) HIV uses an enzyme known as reverse transcriptase to
convert its RNA into DNA. (iii) HIV DNA enters the nucleus of the target cell and inserts itself into
the cells DNA, where it may stay inactive for years. (iv) The infected cell makes many copies of the
original virus, along with some more specialized genetic materials for making longer proteins. (v)
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Figure 2.: The process of HIV replication(from the website of Baylor College of Medicine
https://www.bcm.edu/departments/molecular-virology-and-microbiology/hivaids).
The longer HIV proteins is cut by a enzyme called protease into individual proteins. A new virus
is assembled as long as all components come together. (vi) The virus pushes itself out of the host
cell and takes with it part of the cell membrane. This outer part covers the virus and contains all
of the structures necessary for the virus to bind to a new CD4 cell and begin the virus life cycle
process again. Current treatment strategy involves a combination of drugs that target different steps
of HIVs life cycle such as entry inhibitors that prevent binding of HIV to the CD4 receptor, reverse
transcriptase inhibitors that prevent the HIV RNA from being transcribed into DNA and protease
inhibitors that prevent the assembly.
A T lymphocyte, called CD4 cell, is the major target cell for HIV. The CD4 cell is a subset of
T cells, also known as T helper cell, which express the cluster of differentiation 4 (CD4). These
cells assist other white blood cells in immunologic processes. The normal CD4 cells account for
32% to 68% of total number of lymphocytes and range between 5001600/mL. Without any effective
treatment, the dramatic decrease in CD4 cells results in such a weakened immune system that the
body can no longer fight infections or certain cancers. The mechanisms of CD4 cell death in HIV
infection are still not fully understood. The mechanisms by which HIV can directly induce infected
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cell death include plasma membrane disruption or increased permeability due to continuous budding
of the virion [3], increasing cellular toxicity due to build up of un-integrated liner viral DNA [4] and
inactivation of anti-apoptotic genes [5]. However, a longstanding question in HIV biology is how
HIV viruses kill so many CD4 cells, despite the fact that most of them appear to be “bystander” cells
that are not infected [6]. Recent researches demonstrate that the majority uninfected CD4 cells in
peripheral blood and lymph nodes undergo three types of apoptosis [7], which is a tightly regulated
programmed cell death [8]. Several HIV proteins, such as Env and Vpr, have been found to be able
to up-regulate Fas/FasL gene expression either on the infected cells or neighboring uninfected cells
[9], and these two genes will send signal of apoptosis to these cells.
Without treatment, the average time from acquisition of HIV to an AIDS-defining opportunistic
infection is about 10 years, which is the reason why many people originally thought the rate of HIV
replication and disease process would be slow. But it is not true. Several researches [12, 13, 14]
suggested that HIV replication and the disease process are very vibrant. On average, plasma virions
have a mean lifespan of 0.3 days (half-life = 0.24 days), and the average total HIV-1 production
is 10.3 × 109 per day, the minimum duration of the HIV-1 life cycle in vivo is 1.2 days, and the
average HIV-1 generation time is 2.6 days (generation time is defined as the time from release of
a virion until it infects another cell and causes the release of a new generation of viral particles).
Because the high viral replication rate may result in a high mutation rate, Ho [12] proposed the
treatment strategy of “Hit Hard, Hit Early”. “Hit Hard” requires simultaneously combining different
medications in the treatment, in which “Hit Early” means the treatment should start as early as HIV
infection has been confirmed. Based on 2012 U.S. Department of Health and Human Services
Panel on Antiretroviral Guidelines for Adults and Adolescents [15], the initiation of antiretroviral
therapy (ART) is optional if the CD4 cell count is > 500/mL, moderately recommended if the CD4
cell count is 350 to 500 /mL and strongly recommended if the value is < 350 /mL. Regardless
of the CD4 cell count, ART is strongly recommended if patients have certain conditions such as
pregnancy, history of an AIDS defining illness or hepatitis B (HBV) co-infection. The usual highly
active antiretroviral therapy (HAART) combines three or more different medications such as two
nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI), a non-nucleoside
reverse transcriptase inhibitor (NNRTI) or other such combinations. These HAART regimens have
been proven to be able to reduce the amount of active viruses and in some cases can lower the
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number of active viruses until it is undetectable by current blood testing techniques.
1.2 Research motivation
A longitudinal study refers to an investigation where participant outcomes are collected at multiple
follow-up times yielding multiple measurements on each subject. In AIDS longitudinal studies, HIV
infected patients may be followed over time and monthly measures such as CD4 counts, or viral
load are collected to characterize immune status and disease burden respectively. Such longitudinal
data are correlated within subjects and thus require special statistical techniques for valid analysis
and inference. Further, it is not uncommon for the relationship between an explanatory variable
(e.g., time) and a response variable (e.g., CD4 or viral load) to be nonlinear in the parameters.
Nonlinear mixed-effects (NLME) models provide a tool for analyzing repeated measurements data
by taking into consideration intra- and inter-variability as well as the nonlinear relationship between
the explanatory variable and the response variable.
Various models and inference methods have been used to analyze longitudinal CD4 trajectories
including, but not limited to, parametric linear growth curve model with random effect [17, 16],
piecewise linear with random change-point[18]; and longitudinal viral load trajectories including,
but not limited to, linear and nonlinear regression [19], NLME modeling approach [20, 21], nonpara-
metric NLME modeling approach [22, 23], joint modeling approach via Monte Carlo EM algorithm
[24], and Bayesian NLME modeling approach via Markov chain Monte Carlo (MCMC) procedure
[25]. Those models and methods have provided feasible modeling choice to better understand the
treatment effects of ART.
However, the majority of existing statistical models is based on the assumption that patients are
from a common homogenous population governed by the same mean trajectory; random effects
are used to characterize the large inter-individual variation in addition to time-varying covariates.
Figure 3(a) shows the inter-individual variation in CD4 trajectory through four patients chosen from
a clinical management data set (see Section 3.1 for details of this data set), and Figure 3 (b) shows
the same with viral load trajectory using six patients in an AIDS Clinical Trial (ACTG398) study
[26](see Section 4.2 for details of this study and data). Figure 3(a) suggests four main classes of
CD4 trajectories can be roughly classified into four classes: (i) stable, (solid line, ID: 102), (ii)
increasing steadily, (dashed line, ID: 143), (iii) increasing then stable, (dash-dotted line, ID: 328),
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and (iv) increasing then decreasing, (dotted line, ID: 970). In comparison, Figure 3(b) reveals 3
classes for viral load trajectories: (i) rapid decreasing in a short-term period (solid lines, ID: 31,
105), (ii) rapid decreasing then stable at a low level (dashed lines, ID: 29, 132), and (iii) decreasing
at the beginning, followed by rebound (dotted line, ID: 33, 99).
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Figure 3.: (a) Profile of CD4 cell count from a clinical management database.(b) Profile of viral
load in log10 scale for six representative patients from a clinical trial ACTG398.
Along with these observations, we can assume that, CD4 trajectories can be described with four
distinct classes with each the patients are relatively homogeneous, and viral load trajectories can be
characterized in three classes. A patient’s outcome trajectory thus can be from one of these plausible
empirical classes with some uncertainty. This suggests that we consider a finite mixture of NLME
models to describe the population trajectories of the patients. Instead of assuming individual varia-
tion around a single common mean trajectory, a finite mixture model recognizes that the population
consists of different classes of individuals whose trajectories vary around their own group-specific
mean trajectory. In this sense, finite mixture modeling better captures inter-individual variation and
heterogeneity. Specific applications of finite mixture models such as growth mixture model (GMM)
and latent curve model (LCM) are often employed in social sciences studies [27, 28, 29] to explicitly
model clustered or grouped individual behaviors. However, most finite mixture models are based
on linear (polynomial) [27, 28] or piecewise linear [29] mean functions. Linear models have the
advantages that the associated likelihood function has a closed form [27]. When a mixture model
is extended to incorporate nonlinear mean functions, inferential procedures becomes complex be-
cause a closed form of likelihood function is no longer available. We adopt a Bayesian inferential
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in our effort to model the nonlinear trajectories of CD4 and viral load. It was noticed that, in anal-
ysis of heterogeneous data, finite mixture models not only fit data “better” by recognizing different
classes beyond the influence of covariates, but also provide an efficient modeling-based clustering
and classification. As a co-product of the modeling process, we also obtain probability of an subject
belonging to each class. The estimated probabilities may inform clinicians of the patient’s disease
prognosis. For example, the information could help clinicians would be able to plan for a a follow-
up treatment strategy if they know the proportion of patients who could fall into a particular class
under certain treatment regimen within a given time window.
1.3 Specific aims
Modeling CD4 and viral load trajectories are important in understanding HIV/AIDS prognosis and
treatment effects in HIV/AIDS studies, the CD4 and viral load trajectories exhibit obvious and
sizeable heterogeneity. CD4 and viral load trajectories can identify patients whose trajectories are
of distinct clinical presentation and their explicit characterization in different classes can inform
clinical decision. This research is focused on mixture modeling of HIV/AIDS outcomes with three
specific questions to address:
• First, the finite mixture models for longitudinal data are commonly for linear mean functions.
To extend the mixture models to incorporate nonlinear mean functions the use of traditional in-
ference methods such as the EM algorithm needs to be re-evaluated. Computational complexity
may render certain methods less useful and ineffective. A finite mixture model with nonlinear
mean functions for longitudinal data and associated inference method need better understanding
both theoretically and application wise.
• Second, in order to address the heterogeneity in the CD4 trajectories, specific nonlinear mean
functions are needed for different classes. The nonlinear behavior of CD4 trajectories has not
been well quantified in the literature, and nonlinear functional forms with meaningful interpre-
tation are useful. Besides, it is of clinical interest to able to predict a patient’s membership,
say, at the end of second year based the data from the first year. Developing a model based
prediction of the class membership is useful.
• Third, the approach and methodology developed for CD4 trajectory analysis, can be applied
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for the analysis of viral load with classes of models specific to viral load trajectories. In this
spirit, the methodology developed here can be utilized for modeling progression of other chronic
diseases.
This dissertation research thus is focused on three specific aims:
Aim 1. In Chapter 2, we develop a finite mixture model with distinct nonlinear mean functions and
associated Bayesian inference method.
Aim 2. In Chapter 3, we designed four mean functions based on the Michaelis Menten function for four
trajectory classes for CD4 counts in conjunction with a model-based membership prediction
approach.
Aim 3. In Chapter 4, we apply the methodology to analyze viral load using three latent classes differ-
entiating viral load with or without a rebound.
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Chapter 2
Finite mixture of nonlinear trajectories and Bayesian inference
Finite mixture of nonlinear trajectory models and associated Bayesian inference method are pre-
sented in this chapter in a general form. Although this methodology is motivated by AIDS studies,
the basic concepts of the newly-developed mixture modeling approach can be readily applied under
similar circumstances, especially those of chronic diseases management where we observe disease
management longitudinally with continuous measurement.
2.1 Mixture of nonlinear mixed-effects trajectories
Let yi = (yi1, ..., yini)
T be a vector of observed outcomes (e.g. CD4 counts or viral load) on the ith
individual (i = 1, 2, ..., n) at times tij (j = 1, 2, ..., ni). Assume there is a vector of p covariates, x,
which are measured repeatedly on the ith individual at each time point tij . Some of the covariates
may be time-varying in value, including time tij for example. Therefore individual i has a ni × p
covariate matrix, Xi = (xi1, · · · ,xini)T , xij is the jth column of Xi for individual i at time tij .
Note for a non-time-varying covariate, its value is a constant repeated ni times. Further note that
the set of covariates x includes all available variables. In practice, however, only a subset will be
chosen for a particular model.
Assume that yi follows one of K plausible latent trajectories which are described by mean func-
tions gk(·), k = 1, ...,K. However, it is not predetermined which group the ith individual’s trajec-
tory belongs to. There is an unknown probability that the person’s trajectory belongs to group k. Let
ci be a latent class indicator of individual i, of which the value is unobservable but can assume only
one value among 1 : K, with the probability piik = P (ci = k) (k = 1, · · · ,K) and
∑K
k=1 piik = 1.
Given ci = k a statistical model of growth trajectory can be formulated as follows:
E(yi|Xi,β, bi; ci = k) = gk(Ak,Bk,β, bi,Xi) = (gk(Ak,Bk,β, bi,xi1), ..., gk(Ak,Bk,β, bi,xini))T
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whereAk is a (p×p) indicator matrix that determines what covariates warrant inclusion in the given
model. Ak is essentially an identity matrix Ip with chosen diagonal elements set to 0, corresponding
to the covariates excluded from the model. Bk is also a (p× p) indicator matrix that selects among
the covariates already chosen byAk those that warrant random effects. Because the choices can be
distinct for each trajectory class k,Ak andBk have subscript k.
For model gk, the vector of regression coefficients for individual i can now be expressed as
βki = Akβ +Bkbi, (2.1)
where β = (β1, ..., βp)
T is the vector of population coefficients for all plausible covariates and
bi = (bi1, ..., bip)
T is the individual-specific regression coefficients (random effects) assigned to the
entire set of the plausible covariates. Note that the matrix operationsAkβ andBkbi effectively set
the unwanted coefficients to zero to arrive at the desirable subsets. This is exactly the same as in the
classic regression setup,
Xiβki =XiAkβ +XiBkbi =X
∗
kiβ
∗
k +Z
∗
kib
∗
ki, (2.2)
whereX∗ki =XiAk is a design matrix for class k after removing the corresponding zero-columns;
and β∗k = Akβ is a vector after taking out the zero elements from the product. (Note thatAkAk =
Ak.) Similarly Z∗ki =XiBk is a design matrix for the random effects, and b
∗
ki = Bkbi is a vector
of random coefficients.
The random effects are typically used to describe between-patients variation that are not explained
by difference in patient physiological or clinical characters. In practice it is uncommon that random
effects are attached to a large number of covariates because it is neither biologically necessary nor
statistically supported by the data. Instead only a small number of covariates in the model will be
assessed for potential between-patient variation. In other words, r and s are the number of fixed
effects and random effects in a particular class. In our case we consider the case p > r > s. We
will give examples ofAk andBk in Section 3.2 and 4.3.
Random effects are typically assumed to follow a multivariate normal distributions
bi
iid∼ Np(0,Σ) (2.3)
where Σ (p× p) is the variance-covariance matrix to be estimated.
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By adding error terms to the (mean) model above we have
(yi|Ak,Bk,β, bi,Xi; ci = k) = gk(Ak,Bk,β, bi,Xi) + ei,
ei
iid∼ Nni(0, σ2Ini); (2.4)
or equivalently
(yi|Ak,Bk,β, bi,Xi; ci = k) ∼ Nni(gk(Ak,Bk,β, bi,Xi), σ2Ini). (2.5)
The marginal distribution of the model above over all latent classes is given by
yi ∼
K∑
k=1
piikNni(gk(Ak,Bk,β, bi,Xi), σ
2Ini). (2.6)
This distribution is a mixture of K non-linear mixed-effects (NLME) regression or trajectory mod-
els. The mixture probabilities pii = (pii1, ..., piiK)
T , (i = 1, · · · , n), can be also viewed as the
mixture weights. Model (2.6) is identifiable as long as each component model is identifiable. Here
identifiability also implies the models gk(·) are distinguishable from one to another [36].
This model can be interpreted as a missing data model if the indicator vector c = (c1, · · · , cn)T
is treated as missing. The corresponding complete likelihood is then
(yi, ci) ∼
∏K
k=1[Nni(gk(Ak,Bk,β, bi,Xi), σ
2Ini)Pr(ci = k)]
I(ci=k). (2.7)
It can be shown that
f(yi, ci) = f(yi|ci = k)Pr(ci = k) = f(yi)Pr(ci = k|yi).
2.2 Bayesian inference approaches
Let θ =
{
β,Σ, σ2
}
be the collection of all unknown population parameters in models (2.2), (2.3)
and (2.6). The mixture weights pii in (2.6) will be dealt with separately. To make inference for the
models (2.2), (2.3) and (2.6) and class membership probabilities pii, we take a Bayesian approach
using the Markov chain Monte Carlo (MCMC) procedure [37].
Under the Bayes framework, it is assumed that there are prior information about the parameters
that we are interested in. The prior information is often given in the form of a prior distribution.
The prior distribution may reflect a strong belief so that a parameter is well-centered with a narrow
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range of variation (informative prior, such as a normal distribution with small variance) or lack of
specific knowledge so a non-informative prior (e.g. an uniform distribution or a normal distribution
with large variance) is used. Upon observing the data, a posterior distribution is obtained combing
the data with the prior to update the parameter with newly obtained information.
2.2.1 Prior distributions
Under the Bayes framework, we specify prior distributions for θ as follows.
β ∼ Np(β0,Λ),Σ ∼ IW (Ω, υ), σ2 ∼ IG(ω1, ω2), (2.8)
where the prior distributions are normal (N ), inverse Gamma (IG), and inverse Wishart (IW ) re-
spectively. They are chosen to be mutually independent to facilitate computations [38]. We assume
the hyper-parameter matrices Λ and Ω to be diagonal for convenience. Note that we can choose
non-informative prior such as uniform distributions for selected elements of β when needed.
By definition, the latent indicating variable ci (i = 1, ..., n) follows a Multinomial distribution
(Mul) given the class probabilities pii:
ci ∼ Mul((1, ...,K), (pii1, ..., piiK)). (2.9)
The class probabilities pii = (pii1, ..., piiK)
T are assumed to initially follow a prior Dirichlet distri-
bution (Dir) [39, 40, 41],
pii ∼ Dir(φ1, ..., φK). (2.10)
where φk > 0 (k = 1, · · · ,K) are the hyper parameters to be assigned. In the prior, we do not
consider between-individual variation, i.e. φk, (k = 1, · · · ,K), are free of any covariates. Since the
Dirichlet is a conjugate prior to a Multinomial distribution, the posterrior distribution of pii given ci
(i = 1, · · · , n) is again a Dirichlet distribution.
2.2.2 Posterior distributions
Conditional on ci and and the random effects bi, the conditional distribution of yi is,
(yi|bi;Aci ,Bci ,Xi,β, σ2, ci) ∼ Nni(gci(Aci ,Bci ,β, bi,Xi), σ2Ini). (2.11)
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For notational convenience, let the observed data of the ith individual DATAi = {yi,Xi}, ob-
served data DATA = {DATAi, (i = 1, ..., n)}, b = {bi, i = 1, · · · , n}, c = (c1, · · · , cn)T .
To draw samples from posterior distributions, we derive conditional posterior distributions for all
unknown parameters. Based on Bayes’ theorem, the posterior probability ci = k is given by,
P (ci = k|bi;θ,yi,Xi) = P (ci=k)f(yi|bi,ci=k,θ,X i)f(yi|bi,θ,X i)
=
P (ci=k)f(yi|bi,ci=k,θ,X i)∑K
m=1 P (ci=m)f(yi|bi,ci=m,θ,X i)
,
(2.12)
where f(yi|bi, ci = k,θ,Xi) (k = 1, ...,K) are conditional density functions of yi based on (2.5)
and f(yi|bi,θ,Xi) is a marginal density function of yi based on (2.6). Assuming the prior class
membership probability are the same for all individuals, P (c1 = k) = · · · = P (cn = k) = pik,
model 2.12 becomes
P (ci = k|bi;θ,yi,Xi) = pikf(yi|bi,ci=k,θ,X i)∑K
m=1 pimf(yi|bi,ci=m,θ,X i)
. (2.13)
which means in each iteration of MCMC the prior membership probability is generated from 2.10.
Note that although, to facilitate the implementation, the prior class membership probability are
assumed to be the same for all individuals, the posterior distribution 2.13 can be readily extended to
be dependent on individual covariates, for example,
P (ci = k|bi;θ,yi,Xi, xi) =
P (ci = k|xi)f(yi|bi, ci = k,θ,Xi)∑K
m=1 P (ci = m|xi)f(yi|bi, ci = m,θ,Xi)
,
in which xi is an individual covariate. In this way the posterior membership probability in the
previous iteration is used to be a new prior to update the membership probability.
In this case, 2.13 is used in the MCMC process. So the dependence of piik on yi and x becomes
simplified in that piik it is no longer individual specific, so the notation pik will be used instead. In
this way, each iteration generates pi given ci, (i = 1, · · · , n), using the following distribution
(pi|ν1, ..., νK) ∼ Dir(φ1 + ν1, ..., φK + νK), (2.14)
where νk =
∑n
i=1 I(ci = k), (k = 1, ...,K), in which I(·) is an indicator function[39, 40, 41].
Since Dirichlet distribution is a conjugate prior to multinomial distribution, as mentioned above,
the posterior distribution of pi given ci , (1, · · · , n), which are generated based on 2.13, is also a
Dirichlet distribution.
(β|b,Σ, c,DATA) ∼ Np(β′0,Λ′); (2.15)
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(σ2|b, c,DATA) ∼ IG(ω′1, ω′2); (2.16)
(Σ|b) ∼ IW (Ω′, υ′). (2.17)
In (2.15), (2.16) and (2.17),
Λ′ =
{∑
i
[
ATci(BciΣB
T
ci)
−1
Aci
]
+ Λ−1
}−1
,
β′0 = Λ
′
{∑
i
[
ATci(BciΣB
T
ci)
−1
(Aciβ +Bcibi)
]
+ Λ−1β0
}
;
ω′1 = ω1 + 2
−1∑
i
ni,
ω′2 = ω2 + 2
−1∑
i
[
yi − gci (Aci ,Bci ,β, bi,Xi)
]T [
yi − gci (Aci ,Bci ,β, bi,Xi)
]
;
Ω′ = Ω +
∑
i
bib
T
i ,
υ′ = υ + n.
The full conditional distribution of each bi given the remaining parameters and data, however,
cannot explicitly be expressed. The distribution of (bi|β,Σ, σ2, ci,DATAi) has a density function
that is proportional to
exp{−(2σ2)−1[yi − gci (Aci ,Bci ,β, bi,Xi)]T [yi − gci (Aci ,Bci ,β, bi,Xi)]
−2−1bTi Σ−1bi}.
(2.18)
2.2.3 MCMC algorithm based on conditional posterior distributions
The idea of MCMC lies in that we draw samples for the parameters based on their posterior dis-
tributions given the data and the latent membership indicators. Sufficiently large MCMC samples
reveal the posterior distribution numerically. In the present context, the Gibbs sampler along with
the Metropolis-Hastings (M-H) algorithm can be used to draw samples.
Our mixture model requires two MCMC sequences be drawn simultaneously. One is for the
latent class indicators and the other is for the parameters and individual random effects given the
latent class indicators. We alternate between these two sequence in each MCMC run because it is
necessary to update the latent class indicators as the data models shape up, and derive the posterior
distribution based on the sampled latent class. An important advantage of the above representations
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based on the three-level hierarchical models is that they can be very easily implemented using
the freely available WinBUGS software [42] interacted with a function called bugs in package
R2WinBUGS of the software R.
2.2.4 MCMC implementation and convergence diagnosis
The MCMC sampler was implemented using WinBUGS software [42] interacted with a function
called bugs in a package R2WinBUGS of R. When the MCMC procedure was applied to the
actual clinical data, convergence of the generated samples was assessed using standard tools within
WinBUGS software such as trace plots and Gelman-Rubin (GR) diagnostics [43]. We will illustrate
the use of GR diagnostic in the Section 3.5 and 4.4.
2.2.5 Model selection criteria
The MCMC algorithm under Bayesian framework has made it possible to fit increasingly complex
statistical models with larger number of parameters and determine the best-fitting model candidates.
To determine relevant covariates in the model, a Bayesian selection criterion, known as deviance in-
formation criterion (DIC) suggested by Spiegelhalter et al. [44], can be used. DIC is applicable to
a wide range of statistical models. There are other Bayesian approaches to model selection includ-
ing, for example, posterior model probabilities, Bayes factor, posterior predictive checks (expected
predictive deviance). However, some of these methods are not automatic nor easily reduced to a
unique and single value summary [45]. To compare the candidate models and select covariates, we
examine their DICs.
Assume that the distribution of the data, Y, depends on the parameter vector θ. Spiegelhal-
ter et al. [44] suggested examining the posterior distribution of the deviance statistic defined by
D(θ) = −2logf(Y |θ) + 2logh(Y ) for Bayesian model comparison, where f(Y |θ) is the likeli-
hood function and h(Y ) denotes a fully specified standardizing term that is a function of the data
alone, which has no impact on model selection. For model comparison, we can set h(Y ) = 1, so
we take,
D(θ) = −2logf(Y |θ).
Based on posterior distribution of D(θ), DIC consists of two components as follows:
DIC = D + pD = 2D −D(θ), (2.19)
15
where D = Eθ|Y [D(θ)] = Eθ|Y [−2logf(Y |θ)] is the posterior mean (PM) of deviance, and pD is
the effective number of parameters, defined as the difference between the PM of deviance and de-
viance evaluated at the PM of θ of the parameters. pD can also be considered as a “mean deviance
minus the deviance of the means”. Spiegelhalter et al. [44] showed that such a difference, between
the average of log-likelihood ratios and the likelihood ratio evaluated at the average of the param-
eters, is the key quantity in estimating the degrees of freedom of a test. The effective number of
parameters is the sum of the intraclass correlation coefficients, which essentially measures the sum
of the ratios of the precision in the likelihood to the precision in the posterior. This fact motivates
using pD to be a complexity measure and the effective number of parameters of a model.
Software WinBUGS has a built-in function to compute DIC for general Bayes models, but the
built-in functions cannot compute DIC for mixture models, due to their complex nature. Note that
the likelihood function of a mixture model is a mean ofK components weighted by mixture weights
pi = (pi1, · · · , piK)T . Extra efforts must be taken to write R code interacted with WinBUGS to
compute DIC for mixture models. Celeux et al.[46] presented the calculation of DIC for mixture
models. Following Celeux’s notation, an archetypical example of a K-component mixture model
can be expressed as
f(Y |θ) =∑Kk=1 pikfk(Y |θk), ∑Kk=1 pik = 1, (2.20)
in which θ = {pik,θk, (k = 1, · · · ,K)}, fk, (k = 1, · · · ,K) are probability density functions. The
observed likelihood of model 2.20 is
f(Y |θ) =∏ni=1∑Kk=1 pikfk(Yi|θk). (2.21)
The term D in 2.19 is therefore approximated by MCMC algorithm as
D ≈ −2M−1∑Mm=1 logf(Y |θ(m))
= −2M−1∑Mm=1∑ni=1 log[∑Kk=1 pi(m)k fk(Yi|θ(m)k )], (2.22)
wherem andM are iteration number and total iteration numbers, {pi(m)k ,θ(m)k , (k = 1, · · · ,K)} are
the simulated values of parameters in themth iteration. The termD(θ) in 2.19 is, straightforwardly,
D(θ) = −2logf(Y |θ)
= −2∑ni=1 log[∑Kk=1 pikfk(Yi|θk)], (2.23)
where pik = M−1
∑M
m=1 pi
(m)
k and θk = M
−1∑M
m=1 θ
(m)
k are the MCMC sample means of sim-
ulated values. Based on D and D(θ) from 2.22 and 2.23, DIC can be obtained according to 2.19.
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Models with smaller DIC should be preferred to those with larger DIC. Models are penalized both
by the value of D, which favors a good fit, but also (like AIC and BIC) by the effective number
of parameters pD. Since D will decrease as the number of parameters in a model increases, the pD,
term compensates for this effect by favoring models with a smaller number of parameters.
Besides DIC, we also evaluate model fitting by comparing the values of expected predictive de-
viance (EPD) and residual sum of squares (RSS) obtained from each model. EPD is formulated
by EPD = E[
∑
i,j (yrep,ij − yobs,ij)2], where the predictive value yrep,ij is a replicate of the ob-
served yobs,ij . In other words, yrep,ij is a random sample from the distribution of y given simulated
parameters. The expectation is taken over the posterior distribution of the model parameters θ [47].
RSS is given by
∑
i,j (yobs,ij − yfitted,ij)2 and it is a measure of the discrepancy between the data
and an estimation model. The smaller the value of EPD and RSS, the better fit of the model to the
data.
2.3 Class membership probability depending on covariates
In 2.12, the individual classification depends on individual covariates Xi in an inexplicit way. In
order to predict class membership in the future based currently available data (see Section 3.8 for
details) the proposed finite mixture model can be extended to allow the probabilities of class mem-
bership to depend on covariates explicitly. This could be accomplished by extending pik to be a
function pik(xi), in which xi is a predictor vector [48]. The odds of belonging to class k to belong-
ing to the last class K is modeled in a multinomial logistic regression [27, 29],
ln(pik/piK) = xTi γk, (k = 1, ...,K − 1), (2.24)
where pik is posterior class membership probability defined in (2.12), xi (l× 1) is a vector of inter-
cept and other covariates for subject i, and γk = (γk1, ..., γkl)
T , (k = 1, ...,K − 1), are unknown
parameter vectors. In practice, model (4.21) can be fitted for the mth iteration of MCMC procedure
based on class membership indicators c(m)i = (c
(m)
1 , ..., c
(m)
n )
T
and inference for γk is then made
based on all estimated γ(m)k , (m = 1, ...,M), in which c
(m)
i is class membership indicator vector in
the mth MCMC iteration and M is the total iteration number of posterior samples.
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Chapter 3
Modeling of CD4 Trajectories
In this chapter, we apply the proposed finite mixture model CD4 trajectories.
3.1 Motivating data set
The dataset used for this research is from the clinical database of the Hillsborough County Health
Department (HCHD) HIV/AIDS Special Clinic which is a site of the HIV Research Network. Pa-
tients received care at the HCHD clinic lacked private insurance and depended largely on the Ryan-
White program, a federal program designed specifically for people with HIV/AIDS. The sample of
patients were enrolled into the program between January 2000 and December 2006. Included in the
data is information on antiretroviral drugs prescribed to each patient and the prescription dates. The
stop date of a prescription is also recorded. The use of HAART regimen followed the department
of health and human services (DHHS) guideline. Because many of the tests such as phenotype and
genotype were optional, only a fraction of the patients had such information. The incompleteness
of such data rendered it less useful. This is a typical limitation of clinical management databases.
However, the data set does contain demographics information such as gender, age, risk factors such
as drug use in the past. Table 1 summarized the baseline demographics characteristics and risk fac-
tors by the number of years patients staying in the study. Given CD4 count as outcome and lab tests
for CD4 were ordered quarterly, our inclusion criteria for this particular analysis include: patients
were likely HAART-naive upon enrolling into the program; they had at least five CD4 measures
while staying on in the program. As a result, the final dataset included 1011 patients. Overall, 998
previously naive patients have stayed in study for more than 1 year. Male patients were basically
twice as many as female patients. Nearly half of total patients were black, and mean age was 40.
Heterosexual risk factor was reported in more than 50% of patients. Men having sex with men ac-
counted for 30% of infections; while less than 10% of patients were declared to have acquired HIV
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infection through other risk behaviors.
Table 1: Demographics characteristics by the number of years patients staying in the study.
Characteristic Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Number of patients 1011 998 810 652 459 331 254
Gender
Female 321(31.7%) 314(31.4%) 263(32.5%) 221(33.4%) 143(31.2%) 116(35.0%) 76(29.9%)
Male 689(68.3%) 684(68.6%) 547(67.5%) 431(66.6%) 316(68.8%) 215(65.0%) 178(70.1%)
Race
Black 463(45.8%) 460(46.1%) 416(51.4%) 290(44.5%) 220(47.9%) 142(42.9%) 101(39.8%)
Hispanic 193(19.1%) 189(18.9%) 142(17.5%) 132(20.2%) 90(19.6%) 72(21.8%) 46(18.1%)
White 334(33.0%) 329(33.0%) 234(28.9%) 217(33.3%) 144(31.4%) 117(35.3%) 107(42.1%)
Other 21( 2.1%) 20( 2.0%) 18( 2.2%) 13( 2.0%) 5( 1.1%) 0( 0%) 0( 0%)
Age
Mean(SD) 40.1(9.2) 40.0(9.3) 40.7(9.3) 41.7(8.9) 42.0(9.7) 43.0(8.5) 43.8(9.8)
HIV Risk Behavior
Behavior 1 543(53.7%) 538(53.9%) 450(55.5%) 345(52.9%) 229(49.9%) 166(50.2%) 128(50.4%)
Behavior 2 81( 8.0%) 80( 8.0%) 63( 7.8%) 42( 6.4%) 36( 7.8%) 30( 9.1%) 20( 7.8%)
Behavior 3 322(31.8%) 320(32.1%) 251(31.0%) 235(36.0%) 173(37.7%) 122(36.7%) 97(38.2%)
Behavior 4 10( 1.0%) 8( 0.8%) 6( 0.7%) 2( 0.3%) 1( 0.2%) 1( 0.3%) 1( 0.4%)
Behavior 5 55( 5.4%) 52( 5.2%) 40( 4.9%) 28( 4.3%) 20( 4.4%) 12( 3.6%) 8( 3.1%)
HIV Risk Behavior
1.Heterosexual
2.Intravenous Drug Usage
3.Men having sex with Men
4.Men having sex with Men+intravenous drug use.
5.Other
Give that a large number of HAART regimens were prescribed to this sample of patients, we
grouped HAART regimens according to combination of nucleoside/nucleotide reverse transcriptase
inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitor (PI)
and entry inhibitors(EI), also known as fusion inhibitors. This grouping revealed the following most
common HAART regimens in order of decreasing prescription frequency: 2 NRTIs + 1 NNRTI, 2
NRTIs + 2 PIs, 2 NRTIs + 1 PI, 3 NRTIs. The remaining HAART regimens were prescribed less
frequently, and were grouped as “Others”, including 3 NRTIs + 1 NNRTI, 3 NRTIs + 1 NNRTI +
3PIs, 4 NRTIs, 4 NRTIs + 2PIs, 2 NRTIs + 2PIs + 1 EI and others. Those periods in which HAART
regimen was not prescribed were denoted “no drug”. Note, however, DHHS guideline recommends
an HIV/AIDS patient be on HAART regimen all the time once HAART started. Table 2 shows 332
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of 1011 patients (32.8%) initial treatment combinations were based on 2 NRTIs + 1 NNRTI; 25.7%
(260) and 15.1% (153) were based on 2 NRTIs +2 PIs and 2 NRTIs + 1 PI, respectively. 85 patients
(8.4%) started with 3 NRTIs. Hepatitis C was reported in 16.9% of patients. 73.0% of patients did
not have AIDS defining illness when the initial regimen started. 14.2% of patients had one or more
than one AIDS Co-Morbidity. Figure 4 shows the 4 typical trajectories with HAART starting date
and type information.
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Figure 4.: Profile of CD4 cell count from a clinical management database.
Viral loads were also measured in clinical management, but on a time scheme more frequent than
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Table 2: Baseline HAART regimens and patients’ characteristics by the number of years patients
staying in the study.
Characteristic Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Number of patients 1011 998 810 652 459 331 254
The first HAART
2 NRTIs + 1 PI 153(15.1%) 150(15.0%) 115(14.2%) 101(15.5%) 77(16.7%) 60(18.1%) 55(21.7%)
2 NRTIs + 2 PIs 260(25.7%) 259(25.0%) 205(25.3%) 161(24.7%) 101(22.0%) 81(24.5%) 61(24.0%)
2 NRTIs + 1 NNRTI 332(32.8%) 329(32.9%) 259(32.0%) 195(29.9%) 120(26.1%) 94(28.4%) 87(34.2%)
3 NRTIs 85( 8.4%) 80( 8.0%) 72( 8.9%) 65(10.0%) 57(12.4%) 40(12.1%) 31(12.2%)
Other 181(17.9%) 180(18.0%) 159(19.6%) 130(19.9%) 104(22.6%) 56(16.9%) 20( 7.9%)
Hepatitis C
No co-infection 465(46.0%) 462(46.3%) 364(44.9%) 312(47.8%) 220(47.9%) 158(47.7%) 112(44.1%)
Co-infection 171(16.9%) 165(16.5%) 145(19.0%) 136(20.9%) 88(19.2%) 59(17.8%) 51(20.1%)
Unknown 375(37.1%) 371(37.2%) 301(37.2%) 204(31.3%) 151(32.9%) 114(34.4%) 91(35.8%)
AIDS Defining Illness
No ADI 738(73.0%) 732(73.3%) 583(72.0%) 449(68.9%) 321(69.9%) 248(75.0%) 198(77.9%)
One ADI 202(20.0%) 200(20.0%) 178(22.0%) 159(24.4%) 114(24.8%) 83(25.0%) 56(22.1%)
Two ADIs 40( 3.9%) 39( 3.9%) 30( 3.7%) 26( 4.0%) 15( 3.3%) 0( 0%) 0( 0%)
Three or More ADIs 31( 3.1%) 29( 2.9%) 19( 2.3%) 18( 2.7%) 9( 2.0%) 0( 0%) 0( 0%)
Co-Morbidity
No Co-Morbidity 868(85.9%) 863(85.4%) 697(86.0%) 571(87.6%) 396(86.3%) 280(84.6%) 233(91.2%)
One 110(10.9%) 105(10.5%) 98(12.1%) 74(11.3%) 60(13.1%) 51(15.4%) 21( 8.8%)
Two or more 33( 3.3%) 30( 3.0%) 15( 1.9%) 7( 1.1%) 3( 0.1%) 0( 0%) 0( 0%)
CD4 Count
CD4 ≤ 50 327(32.3%) 325(32.1%) 270(33.3%) 223(34.2%) 179(39.0%) 119(35.9%) 98(38.6%)
50 < CD4 ≤200 414(40.9%) 410(40.6%) 332(41.0%) 246(37.7%) 129(28.1%) 98(29.6%) 60(23.6%)
200< CD4 ≤350 170(16.8%) 168(16.6%) 145(17.9%) 125(19.2%) 96(20.9%) 72(21.7%) 61(24.0%)
CD4 >350 100( 9.9%) 95( 9.4%) 63( 7.7%) 58( 8.9%) 55(12.0%) 42(12.7%) 35(13.8%)
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CD4 count. Note however, that tests for viral load and CD4 might not be performed and recorded on
the same date even if the tests were ordered on the same date. To reconcile this time misalignment,
we used the viral load that was measured at a time closest to the current CD4 date within the prior 6
months or 2 days after as an “imputed” value corresponding to current CD4. The log-transformation
of viral load was used in the analysis to stabilize the variation of the measurement errors, which
tended to increase with the value of the viral load.
Because many of the tests such as phenotype and genotype were optional, only a fraction of
the patients had such information, rendering it less useful, a typical limitation of many clinical
management databases. Demographics information such as gender, age, risk factors such as drug
use, were also tested in the model but they showed no significant effects on the CD4 trajectories. So
that, they were not included in this analysis.
3.2 Mixture components specification based on Michaelis Menten function
The Michaelis-Menten model [49] is widely used to quantify enzyme kinetics. In enzyme kinetics a
substrate S binds reversibly to an enzyme E to form an enzyme-substrate complex ES, which then
reacts irreversibly to generate a product P and to regenerate the free enzyme E. This system can be
represented schematically as follows:
E + S ⇀↽ ES → E + P
The Michaelis-Menten quantifies the reaction velocity as:
v =
Vmax[S]
KM + [S]
where Vmax represents the maximum velocity achievable by the system, when substrate concentra-
tion [S] increases to reach a saturation level; KM (Michaelis constant) is the substrate concentration
at which the reaction velocity is 50% of the Vmax.
Figure 5 presents the reaction velocity as a function of substrate concentration [S] under the
Michaelis-Menten equation, with Vmax = 200 and KM = 200.
We adopted this classical Michaelis-Menten model to describe different classes of CD4 trajecto-
ries as follows.
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Figure 5.: Reaction velocity under the Michaelis-Menten equation with Vmax = 200 and KM =
200.
1. Class 1: stable around a constant level β1
CD4(t) = β1, (3.1)
2. Class 2: steady increase from baseline level, β1
CD4(t) = β1 +
β2tβ4+β5
β3+tβ4
, (3.2)
3. Class 3: steady increase and remaining stable
CD4(t) = β1 +
β2tβ4
β3+tβ4
, (3.3)
4. Class 4: increase followed by a decrease
CD4(t) = β1 +
β2tβ4
β3+tβ4+β6
. (3.4)
In (3.1), (3.2), (3.3) and (3.4), all parameters are positive (β1, β2, β3, β4, β5, β6 > 0). Figure 6
presents the behaviour of functions (3.1), (3.2), (3.3) and (3.4), with β1 = 300, β2 = 300, β3 = 333,
β4 = 1, β5 = 1, and β6 = 1.3. To convert the four trajectory classes (3.1-3.4) into regression type of
models, it is necessary to incorporate covariates as well as random effects into the basic parameters
β1 –β6. Although in principle covariates and random effects can be incorporated into each and
every of the basic parameter, we will focus on beta2 and beta3 both for illustration purpose and for
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practicality because beta2 and beta3 are the key kinetic parameters that dominate the shape of the
trajectory. From clinical standpoint, the four classes may represent stages of disease progression in
increasing severity. And these four classes appear to capture the main characteristics of the CD4
trajectories observed in this dataset.
3.3 Regression Models
To convert the kinetic models to regression models, let us consider including, in addition to time,
three covariates in the models: (z1, z2, z3) = (viral load, HAART regimens, baseline CD4). Among
them viral load and HAART are time varying. As we have pointed out at the end of Section 3.2, we
focus on two kinetic parameters for setting up the regression models: β2 and β3. Specifically,
β2 = β20 + β21z1 + β22z2 + β23z3,
β3 = β30 + β31z1 + β32z2 + β33z3.
As a result the vector of mean parameters beta is given by
β = (β1, β20, β21, β22, β23, β30, β31, β32, β33, β4, β5, β6).
Correspondingly, the design matrix for the ith patient is
Xi = (xi1, ..., xij , ..., xini)
T
with the observation vector at time j to be xij = (tij , z1ij , z2ij , z3i, z1ij , z2ij , z3i)
T . The repetition
columns of covariates in the design matrix tailors to the needs of nonlinear models. It is well
recognized that individual CD4 at baselines can be substantially heterogeneous. In our sample, it
varies from less than 50 to above 2300. The baseline CD4 not only reflected the disease prognosis
at the point in time, but also influenced treatment regimens to be applied to the patient (reference
to DHHS guideline)[59]. We found it difficult to describe the variation in baseline CD4 using a
single continuous function. As a result, we grouped patients according to their baseline CD4 level,
starting from group 1 of CD4 0 to 100, with increment of 100 thereafter. We then replace β1 by
group specific β1l. Although β1l can be estimated for each group, a decision was made to fix it to
the middle point of the group interval in conjunction with individual specific random effect. With
appropriately definedAk andBk, we can define regression models for CD4 trajectories as follows.
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Figure 6.: Behaviour of mean functions 4 classes of trajectories.
1. Class 1: stable around a constant level
g1(A1,B1,β, bi,Xi) = β1l + b1i, (3.5)
where
A1 = diag(1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0),
B1 = diag(1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0).
Here diag represents a diagonal matrix. βl the middle level of CD4 assuming patient’s baseline
CD4 is in the lth-interval.
2. Class 2: steady increase from baseline level
g2(A2,B2,β, bi,Xi) = β1l + b1i +
β2it
β4i+β5i
ij
β3i+t
β4i
ij
, (3.6)
where
β2i = β20 + b20i + z1ijβ21 + z2ijβ22 + z3iβ23,
β3i = β30 + b30i + z1ijβ31 + z2ijβ32 + z3iβ33,
β4i = β5 + b4i, β5i = β5 + b5i,
A2 = diag(1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0),B2 = diag(1, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1, 0),
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3. Class 3: steady increase and remaining stable
g3(A3,B3,β, bi,Xi) = β1l + b1i +
β2it
β4i
β3i+t
β4i
ij
, (3.7)
where β2i, β3i, and β4i are the same to those in (3.6),
A3 = diag(1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 0),B3 = diag(1, 1, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0).
4. Class 4: increase followed by a decrease
g4(A4,B4,β, bi,Xi) = β1l + b1i +
β2it
β4i
β3i+t
β4i+β6i
ij
. (3.8)
where beta1l, β2i, β3i, and β4i are the same as those in (3.6), and β6i = β6 + b6i,
A4 = diag(1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0, 1),B4 = diag(1, 1, 0, 0, 0, 1, 0, 0, 0, 1, 0, 1).
3.4 Candidate models
We considered the following six models with different combinations of covaraites in regression
models for beta2i or beta3i.
• Model I: including viral load and HAART in parameter β2i.
• Model II: including viral load, HAART, and ordinal baseline CD4 in parameter β2i.
• Model III: including viral load and HAART in both parameters β2i and β3i.
• Model IV: including viral load, HAART, and categorical baseline CD4 in parameter β2i.
• Model V: including viral load and HAART in parameter β3i.
• Model VI: including viral load, HAART, and logarithm transformed baseline CD4 in parameter
β2i.
We investigated the following two scenarios. First, we investigated CD4 baseline as a covariat in
Models I, II, IV, and VI. In Models II and IV, baseline CD4 was categorized into 4 groups, group 1:
≤ 50, group 2: > 50 and ≤ 200, group 3: > 200 and ≤ 350, group 4: > 350, the ordinal score 1
to 4 was assigned to each individual in Model II, but a 4–level nominal scale was used in Model IV.
Model VI used log-CD4 as the covariates, whereas Model II used the original CD4 in contrast with
Model I which does not include CD4. Second, we investigated whether to put those covariates, in
β2i or β3i, or both. The comparison results will be shown in Section 3.6.
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3.5 MCMC implementation
To carry out the Bayesian inference, we took weakly-informative prior distributions for the param-
eters in Models I, II, III, IV, V and VI. In particular, (i) the prior of β3 and power parameters in the
population parameter vector β, such as β4, β5 and β6, were taken to be uniform distribution U(0, 3);
(ii) the prior for the remaining mean parameters of β were taken to be independent normal distribu-
tionN(0, 100) for each element; (iii) we assume a noninformative inverse Gamma prior distribution
IG(0.01, 0.01), which has mean 1 and variance 100, for variance parameter σ2 ; (iv) the priors for
the variance-covariance matrices of the random-effects Σ was taken to be inverse Wishart distribu-
tions IW (Ω, υ), where the diagonal elements for diagonal variance matrix Ω were 0.01, and υ = 4;
and (v) finally, we set hyper-parameters of Dirichlet distribution in 2.10, φ1 = φ2 = φ3 = φ4 = 1,
assuming individuals have equal probabilities of coming from any one of four classes initially.
The MCMC sampler was implemented usingWinBUGS software [42] interacting with R through
a function called bugs in a package R2WinBUGS. When the MCMC procedure was applied to the
actual clinical data, convergence of the generated samples was assessed using standard tools within
WinBUGS software such as trace plots and Gelman-Rubin (GR) diagnostics [43]. Figure 7 shows
the dynamic version of GR diagnostics using results of Model VI as obtained from the WinBUGS
software for the representative parameters where the three curves are given: the middle and bottom
curves below the dashed horizontal line (indicated by the value one) represent the pooled posterior
variance (Vˆ ) and average within-sample variance (W ), respectively, and the top curve represents
their ratio (Rˆ). It is seen that Rˆ tends to 1, and Vˆ and W will stabilize as the number of iterations
increase indicating that the algorithm has approached convergence. Figures 8 and 9 show the trace
plots and the histograms of β10–β30, and β4–β6. While sampled values fluctuates, the fluctuation
tends to stabilizes when the posterior distribution stabilizes. Thus when the horizontal line, which
is the cumulative average of the parameter estimate, on each plot of the trace plots is stable we
consider convergence reached. The histograms show the distribution of each parameter and all look
normally distributed.
Upon convergence, observed, we proposed that, after an initial 50,000 burn-in iterations of three
chains of length 100,000, we retained every 50th MCMC sample from the next 50,000 for each
chain. Thus, we obtained a total of 3,000 samples of targeted posterior distributions of the unknown
parameters for statistical inference.
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Figure 7.: Gelman-Rubin (GR) diagnostic plot based on the NLME mixture model with three
Markov chains as obtained from the WinBUGS software for representative parameters.
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Figure 8.: Traceplots of MCMC parameter samples (β1,β20,β30,β4,β5,β6 and σ2).
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Figure 9.: Histograms of MCMC parameter samples (β1,β20,β30,β4,β5,β6 and σ2).
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3.6 Model comparison and selection
To select the “best” model for the data under consideration, we used DIC, a Bayesian selection cri-
terion. As with other model selection criteria, DIC is not intended for identification of the “correct”
model, but rather merely as a method of comparing a collection of alternative models. EPD and
RSS as supplemental criteria were also used. The detailed information of DIC, EPD and RSS can
be found in Section 2.2.5. Table 3 presents the DIC, EPD and RSS values among the six competing
models. It can be seen that the Model VI with all covariates in parameter β2i produce better fit than
all other Models in terms of DIC, as well as EPD and RSS. Thus, Model VI is selected as the
model for subsequent inference such as class membership prediction.
Table 3: The deviance information criterion (DIC), expected predictive deviance (EPD), residual
sum of squares (RSS) based on all candidate models.
Model DIC EPD RSS
I 32851 7.91 62589
II 33149 8.24 63027
III 34480 8.81 63577
IV 34906 9.03 63621
V 33592 8.56 63189
VI 32367 7.32 62173
The population posterior mean (PM), the corresponding standard deviation (SD) and 95% credi-
ble interval (CI) for fixed-effect parameters based on the Models I-VI are given in Tables 4–6. The
following findings are observed based on the estimated results. First, for the key kinetic parameters,
β2 and β3, which are the “altitude” of CD4 trajectories and the time CD4 increase to the half of
the “altitude”, not taking the effects of covariates into consideration, the results based on all six
candidate models are comparable, even though the estimate of β2 from Model I is higher than that
from Model VI. Second, for β3 which determine the time when the trajectories increase to the half
of the altitude, β3, estimates from all six models are around 0.5. Third, the viral load is associated
with peak negatively, which mean the higher the viral load is the lower CD4 can go. The coefficients
from all candidate models are negative and statistically significant, since the 95% CIs do not contain
zero. Fourth, because parameters β2 and β3 are not independent in the Michaelis-Menten system it
is not necessary to have covariates in regression models for both parameters. That Model III gives
high DIC, EPD and RSS than other models is empirical evidence towards that direction. Fifth,
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logarithm of baseline CD4 is marginally significant in its association with the trajectory, since the
95% credible limit excludes zero. The term was therefore retained in Model VI, since this model is
the best in terms of all model selection criteria. Lastly but importantly, based on the coefficients of
HAART treatments in β2, the greatest peak CD4 attainable appears to be associated with 2 NRTIs
+ 2PIs, followed by 3 NRTIs, 2 NRTIs + 1PI and 2 NRTIs + 1 NNRTI. More specifically, the four
regimens would improve the peak CD4 counts by 44.6, 33.5, 31.1 and 27.7, respectively. In con-
trast, the remaining HAART regimens “others” led to the least improvement in peak CD4 at 16.2
only.
Table 4: Posterior mean (PM ), standard deviation (SD), 95% credible interval (CI) for intercepts
β1,β20,β30,β4,β5,β6 and σ2.
Model β1 β20 β30 β4 β5 β6
I PM 19.6 85.7 0.51 0.96 0.88 1.97
LCI 15.8 78.8 0.36 0.79 0.76 1.59
UCI 22.4 90.4 0.69 1.21 1.01 2.34
SD 2.32 3.55 0.09 0.14 0.11 0.24
II PM 25.8 72.6 0.44 0.89 0.85 1.91
LCI 22.0 65.0 0.26 0.73 0.70 1.54
UCI 28.1 76.9 0.55 1.08 0.99 2.37
SD 2.26 3.37 0.10 0.08 0.08 0.27
III PM 31.1 83.4 0.55 0.88 1.12 1.65
LCI 28.0 77.7 0.40 0.71 0.98 1.29
UCI 33.9 90.5 0.73 0.99 1.23 1.96
SD 2.17 3.57 0.12 0.07 0.10 0.34
IV PM 25.6 78.7 0.49 0.92 0.98 1.74
LCI 24.0 73.5 0.30 0.77 0.86 1.33
UCI 29.1 84.1 0.65 1.14 1.17 2.31
SD 2.12 3.46 0.11 0.12 0.09 0.23
V PM 18.4 80.2 0.42 0.91 1.04 1.65
LCI 14.8 75.3 0.27 0.74 0.91 1.25
UCI 22.1 86.1 0.59 1.42 1.24 1.98
SD 1.79 3.07 0.07 0.11 0.09 0.22
VI PM 22.5 76.4 0.47 0.84 0.93 1.83
LCI 18.1 70.1 0.31 0.66 0.79 1.44
UCI 25.9 81.8 0.62 1.02 1.06 2.26
SD 1.92 3.23 0.08 0.09 0.07 0.25
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Table 6: Posterior mean (PM ), standard deviation (SD) and credible interval (CI) for regression
coefficients of covariates in the model for β3, and corresponding standard deviation (SD), lower
limit (LCI ) and upper limit (UCI ) of 95% equal-tail credible interval (CI).
Model HAAR
log(VL) N2NN1 N2P2 N2P1 N3 Others
I PM
LCI
UCI
SD
II PM
LCI
UCI
SD
III PM -0.0010 -0.0125 0.0190 -0.0477 -0.0684 -0.0255
LCI -0.0110 -0.0505 -0.0217 -0.0975 -0.1264 -0.0547
UCI 0.0105 0.0569 0.0569 0.0032 0.0060 0.0041
SD 0.0056 0.0203 0.0202 0.0257 0.0308 0.0149
IV PM
LCI
UCI
SD
V PM 0.0118 -0.03491 -0.0774 -0.0349 -0.0897 -0.0366
LCI 0.0032 -0.06386 -0.1192 -0.0638 -0.1455 -0.0658
UCI 0.0208 -0.00295 -0.0355 -0.0030 -0.0351 -0.0078
SD 0.0044 0.0150 0.0219 0.0150 0.0279 0.0143
VI PM
LCI
UCI
SD
In summary, our results suggest that among six candidate models Model VI is slightly better fit
model based on all model selection criteria. In the following section we further report our results
for model VI below.
3.7 Further results from model VI
One objective of this data analysis is to identify and classify all individuals into clinically sensible
groups based on their CD4 trajectories. Our empirical analysis suggested 4 classes of CD4 tra-
jectories: (i) stable, (ii) steady increase, (iii) increase first and remaining stable, and (iv) increase
followed by decrease. Although subclasses are possible, these four classes represent the majority
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of CD4 trajectories observed in this sample of patients. The mixture modeling enables us to obtain
a summary of class membership at both the population and individual levels. At population level,
the MCMC procedure yields samples from the posterior distribution of pi = (pi1, pi2, pi3, pi4)
T , the
population proportion of individuals in each class as given in (2.14). The estimates and their 95%
equal-tail CIs are shown in Table 7. It can be seen that class 3 (increase first and remaining sta-
ble) had the largest proportion (35.29%) followed by class 2 (steady increase) (31.45%) and class 4
(increase followed by a decrease ) (24.89%), and class 1 had the lowest proportion (8.28%) (stable).
At individual level, the posterior probability, pik = E[I(ci = k)], of individual i belonging to
the kth (k = 1, 2, 3, 4) class, can be approximated by 1M
∑M
m=1 I(c
(m)
i = k), over the sample c
(m)
i
of class membership of individual i drawn from the posterior distribution (2.12), (m = 1, ...,M ).
Individual classification probabilities are in barplot (Figure 10 for 30 randomly selected individuals.
These individual classification probabilities help clinical diagnosis of disease progression stage. In
addition to Figure9, Table 8 shows posterior classification probabilities for the four patients shown
in Figure 3(a). The classification probabilities and the trajectory class membership suggested in
Figure 3(a) appear to match well. The trajectory of patient 102 appears to be that of class 1 because
the CD4 counts fluctuated moderately; meanwhile the model-based classification yielded a proba-
bility 95% of being in class 1. The CD4 counts of the patient 143 increased steadily through the
course of the follow-up, as a result the model classifies the trajectory into class 2 with a probability
of 99%. Likewise, the CD4 counts of the patient 328 was classified into class 3 with a probability
100%. Finally, patient 970 was classified into class 4 with a probability of 94% because his/her
CD4 counts increased at the beginning but decreased later, with probability being 94%.
Table 7: Population proportion and 95% equal-tail credible interval (CI).
Class Proportion(pi) 95% CI
1 8.28 % (6.25, 10.64%)
2 31.45% (29.07, 33.75%)
3 35.29% (33.73, 37.47%)
4 24.98% (22.83, 26.56%)
The mathematical form of Model VI can be constructed for population mean using the estimates
of the model parameters given in Table 4–6. In particular, the peak of CD4 trajectory is given by
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Figure 10.: Posterior probabilities of belonging to 4 trajectory classes for 30 patients(from the 51st
to the 80th patient).
Table 8: Individual posterior probabilities of belonging to 4 trajectory classes for four representa-
tive patients.
Class Patient ID pi1 pi2 pi3 pi4
1 102 95% 0 % 1 % 4 %
2 143 0 % 99 % 1 % 0 %
3 328 0 % 0 % 100% 0 %
4 970 0 % 0 % 6 % 94 %
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the equation by
β2 = 76.4−15.3×log(viral load)+27.7×N2NN1+44.6×N2P2+31.1×N2P1+33.5×N3+16.2×Others
+9.3× log(CD40)
, (only applicable to classes 2, 3 and 4), where viral load is a time-varying covariate and CD40 is
the baseline CD4 value. At the population level, CD4 trajectories are represented by the following
for the four classes:
1. Class 1: stable
ˆCD41(t) = βl + 22.5, (3.9)
2. Class 2: steady increase
ˆCD42(t) = βl + 22.5 +
β2t1.77
0.47+t0.84
, (3.10)
3. Class 3: increase first and remaining stable
ˆCD43(t) = βl + 22.5 +
β2t0.84
0.47+t0.84
, (3.11)
4. Class 4: increase followed by decrease
ˆCD44(t) = βl + 22.5 +
β2t0.84
0.47+t2.67
. (3.12)
3.8 Class membership prediction
Given a reasonably well fit model, one potential application is prediction of future class of trajectory
(forecasting) given current status including current class of CD4 trajectory. Our mixture model
allows for simultaneous model fitting and membership classification. This can be done using the
multinomial logistic regression model for the class probability discussed in Section 2.3. The allows
for dependence of posterior membership probability on selected predictors. It is of clinical interest
to predict a patient’s CD4 trajectory class as an aid for disease staging and prognosis. For example,
it would be interesting at the end of one year to forecast the CD4 trajectory within two year utilizing
knowledge of the current trajectory and HAART regimens being used, etc. In other words, we
would like to estimate a patients class membership probability at the end of the second year, with
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only information on the patient by the first year. In this section we discuss the process of class
membership prediction. We illustrate the process using year one results to predict year two outcome.
The approach can be easily extended setting of different time points or intervals.
3.8.1 Current class membership probability
To predict future CD4 trajectory using currently available clinical information of the patients, a sum-
mary of current CD4 trajectory is highly useful. To this end, it is necessary to summarize a patient’s
current trajectory. For this purpose, the whole data set was truncated at the end of the first year, and
the mixture model was fitted to the year one data. We obtain the class membership probabilities
(p11i, p12i, p13i, p14i) (i = 1, · · · , n). Clinically the four classes of trajectory somewhat reflect four
stages of the disease progression in terms CD4. Among HAART naive patients, stable (class 1) may
be viewed as an earlier stage where the immune system has not seen a meaningful decline; upon
initial treatment using HAART, initial response is typically a boost of CD4 in the patient so CD4
counts increase steadily over a certain period of time (class 2); upon loosing the initial drug effects,
improvement in CD4 may stagnated, resulting in class 3; finally, when patient immune system is
not responding to treatments, the trajectory of class 4 is likely to follow. Hence the four classes may
roughly echo progressively deteriorating stages of disease prognosis, we therefore assign scores 1-4
to classes 1, 2, 3 and 4 respectively.
s1i =
∑
k
kp1ki, (k = 1, · · · , 4),
where p1ki is current posterior membership probability for the ith patient. Figure 11 shows the class
membership probabilities based on year 1 data for the first 30 patients.
3.8.2 Class membership probability based on truncated year 2 data
Similarly, we can fit the mixture model for the data truncated at the end of year 2 and obtain class
membership probabilities. Figure 12 shows class membership probability based on truncated year
2 data.
With the estimated classification probabilities using the year two data, a multinomial logistic re-
gression described in section 2.3 can be fitted. The covariates in the multinomial logistic regression
model include, among others, the class score s1i derived from year 1 data and year 1 model, number
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Figure 11.: Class membership probabilities for the first 30 patients at the end of year one.
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Figure 12.: Class membership probability based truncated year two data.
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of HAARTs in the first year, and the CD4 baseline at the beginning of the first year. Table 9 summa-
rizes the estimated posterior mean (PM ) for γ1 − γ3, and corresponding 95% equal-tail credible
interval (in the parenthesis) in membership prediction multinomial logistic regression.
Table 9: Posterior mean (PM ) for γ1 − γ3 (95% CI) in multinomial logistic predictive model for
year two membership.
Covariate vector Intercept Probability score(×10−2) number of HAARTs CD4 baseline(×10−4)
γ1 29.8(24.3,34.2) 2.9(2.2,3.5) -11.3(-13.6,-9.8) 3.8(3.3, 4.3)
γ2 30.2(27.1,33.9) 5.0(4.1,6.6) -9.9(-11.7,-8.4) 3.6(3.1,4.2)
γ3 12.2(10.6,14.5) 12.9(10.3,15.2) -3.5(-4.2,-2.9) 0.5(0.4,0.6)
3.8.3 Predicting class membership at the end of year 2
Supposing there are new patients who only have year one data, we can a fit a mixture model to ob-
tain their membership probability, and, then, the membership score. Together with their numbers of
HAART, and baseline CD4 information, based on the logistic results shown in Table 9, we can ob-
tain the predicted class membership probabilities. Figure 13 shows the predicted class membership
probabilities of the first 30 patients.
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Figure 13.: Predicted class membership probabilities at year 2 suing truncated year one data and
model.
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3.8.4 Evaluation of prediction
The probabilities shown in Figure 12 are based on information from the first and second year, and
the probabilities shown in Figure 13 are based on only information from the first year. We need to
evaluate the agreement of two sets of probabilities. Let s1i and s2i be the membership score of the
ith patient based on the year one and two data, respectively, and let s′2i be the predicted membership
score of the ith patient for the second year based on year one data. Similarly, let p1i and p2i be the
membership probabilities of the ith patient based on the year one and two data, respectively, and let
p′2i be the predicted membership probabilities of the ith patient for the second year based on year
one data. Towards this end, to evaluate the prediction accuracy, we need to evaluate the agreement
between s2i and s′2i, (i = 1, · · · , n). Let c = (1, 2, 3, 4)T ; define statistic R2i be,
R2i =
(s′2i−s2i)2
Vs′2
, (3.13)
in which Vs′2 = c
TVp′2c. Vp′2 is the variance covariance of p
′
2i, (i = 1, · · · , n). In practice, Vp′2 can
be estimated based on all predicted probability, p′2i (i = 1, · · · , n), from the multinomial logistic
regression. After some simplification, we obtain
E(R2i ) = 1 +
[E(s′2i)−s2i]2
Vs′2
. (3.14)
Then, after assume s′2i, (i = 1, · · · , n), are normally distributed and s2i, (i = 1, · · · , n), are known
constants, it can shown that R2 =
∑
i(R
2
i ) asymptotically follows a noncentral Chi-square distri-
bution with a non-centrality parameter λ =
∑
i
[E(s′2i)−s2i]2
Vs′2
and a degree of freedom n−m, where
n and m are number of patients and unknown parameters in the mixture model, respectively.
In this case,
Vp′2 =

0.090 −0.035 −0.028 0.044
−0.035 0.152 −0.002 0.071
−0.028 −0.002 0.111 −0.007
0.044 0.071 −0.007 0.143
 ,
and Vs′2 = 4.97, R
2 =
∑
iR
2
i = 842.5, n = 810, λ = 32.5. It is not easy to determine the number
of parameters, m, in a complex mixture model, for example, m could be 25 or 14 if we do or do not
take the variance-covariance parameters into consideration. The test results are shown in Table 10.
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Table 10: Test results based on non-central Chisq distribution.
n m DF λ R2 p
810 14 796 32.5 842.5 0.6376
810 25 785 32.5 842.5 0.7314
We fail to detect any statistically significant difference between the scores based on observed data
and prediction, since p values are greater than 0.05.
3.8.5 Class membership transition matrices
For notation convenience, let p1i = (p11i, p12i, p13i, p14i)
T be the class membership probabilities
of the ith patient, using the year 1 data, p2i = (p21i, p22i, p23i, p24i)
T be the class membership
probabilities of the ith patient, using the year 2 data, and p′2i = (p′21i, p′22i, p′23i, p′24i)T be the
predicted class membership probabilities of the ith patient at the end of year 2, using the year 1
data. We define an individual probability distribution matrix between p1i and p2i as,
D(12)i = p1ip
T
2i. (3.15)
Then, the mean probability distribution matrix is
D(12) = n
−1∑n
i=1D(12)i. (3.16)
The population transition matrix, T (12), is defined as
T (12) =
([
D(12)(1)/sum(D(12)(1))
]T
, · · · , [D(12)(4)/sum(D(12)(4))]T)T , (3.17)
in whichD(12)(k), (k = 1, · · · , 4), is the kth row ofD(12).
Similarly we can define probability distribution matrix between p1i and p′2i of the ith patient as
D
(12′)i = p1i(p
′
2i)
T . (3.18)
Then, the mean probability distribution matrix is
D
(12′) = n
−1∑n
i=1D(12′)i. (3.19)
The population transition matrix, T
(12′), is defined as
T
(12′) =
([
D
(12′)(1)/sum(D(12′)(1))
]T
, · · · ,
[
D
(12′)(4)/sum(D(12′)(4))
]T)T
, (3.20)
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in whichD
(12′)(k), (k = 1, · · · , 4), is the kth row ofD(12′).
Similar to equations 3.15–3.20, we can define mean transition matrices T (23) and T (23′), T (34)
and T
(34′), T (45) and T (45′), and T (56) and T (56′). It is obvious that the closer T (m(m+1)) and
T
(m(m+1)′), (m = 1, · · · , 5), are, the more accurate the prediction is. The mean transition matrices
T (12) and T (12′) are listed below.
T (12) =

0.31 0.30 0.29 0.10
0 0.61 0.25 0.14
0 0.25 0.53 0.18
0 0.13 0.29 0.58
 ,
T
(12′) =

0.30 0.31 0.28 0.11
0 0.55 0.27 0.18
0 0.30 0.47 0.23
0 0.14 0.31 0.55
 .
We compare the determinants, traces and eigenvalues of T (12) and T (12′) to examine who close they
are to each other. det(T (12)) = 0.037 and det(T (12′)) = 0.022, in which det denotes determinant;
trace(T (12)) = 2.03 and trace(T (12′)) = 1.87; the maximum eigenvalues of T (12) and T (12′)
are 0.98 and 1 respectively, and the minimum eigenvalues of T (12) and T (12′) are 0.28 and 0.18
respectively. Based on determinant, trace and eigenvalues, T (12) and T (12′) are close to each other,
which proves the accuracy of prediction.
Table 11: Closeness evaluation between mean transition matrices T (12) and T (12′).
Items T (12) T (12′) Difference percentage
Determinant 0.037 0.022 40.5%
Trace 2.03 1.87 7.9%
Minimum eigenvalue 0.28 0.18 35.7%
Maximum eigenvalue 0.98 1.00 2.0%
The process demonstrated in Section 3.8.1-3.8.3, can be repeated to predict class membership of
the third year based year 2 data, and so on so forth. Table 12 show the results of the multinormial
regressions from the third year to the sixth year for class membership predictions. Given a new
patient, based on Table 12, can we predict the class membership probability.
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Chapter 4
Viral load trajectories analysis
4.1 HIV viral load dynamic models
Three differential equations are used to describe corresponding parts in the process of HIV infection,
which are target uninfected cell T, virus V and infected cell T ∗.
dT
dt = ρ− dT − kV T
dT ∗
dt = kV T − δT ∗
dV
dt = ηT
∗ − cV
(4.1)
where ρ and d are producing and death rates of T, respectively; V is removed from a body at rate c
and infects the target cells T to T ∗ at rate of k; δ and η are the death rate and virus producing rate of
T ∗, respectively. (4.1) is a system of nonlinear ordinary differential equations (ODE). Even though
(4.1) does have any closed form solution, we can derive various approximations.
When no T is infected, it is noted that V = 0 , T ∗ = 0 and uninfected cells T are at equilibrium
as T = ρ/d. Let t = 0 be the time of virus infection. Supposing the T are infected with a certain
amount of virus, the initial conditions are T0 = ρ/d, T ∗0 = 0 and V0. Whether the virus can grow and
establish an infection or not depends on a crucial quantity called basic reproductive ratioR, which is
defined as the number of newly infected cells arising from one infected cell when almost all cells are
uninfected and R = ρkηdδc . If R < 1, the virus would not spread, since every infected cell would not
on average produce more than one new infected cell. When the infection starts withN infected cells,
it can be expected that, on average, there would be roughly lnN/ln(1 − R) rounds of replications
before the virus population dying out. On the other hand, when R > 1, every infected cell would
produce more than one newly infected cell. It is guaranteed that an explosive multiplication of virus
would be generated, as V (t) = V0 exp(rt), in which r is the exponential growth rate of the virus
population and it is given by the larger root of the equation r2 + (δ + c)R + δc(1 − r2) = 0, the
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approximation of r = δ(R − 1), which means each infected cell produces R newly infected cells
before dying. Virus growth will not continue indefinitely because the supply of uninfected cells is
limited.
The viral load decrease sharply, at the very beginning of initiation of HAART treatment. This
change with time can be expressed by the differential equation as, dV/dt = P − λV , where P is
the viral production rate, λ is the decay rate of viral load, and V is the HIV viral load in plasma.
Assuming a pretreatment steady state exists, dV/dt = 0, and a perfect treatment effect that no new
infection or new virion produced, the HIV dynamics can be expressed as a simple one-exponential
equation [50]:
V (t) = V (0) exp(−λt) (4.2)
where V (0) is the viral load at the baseline and V (t) is the viral load at time t. Equation (4.2) can
only reasonably describe the behavior of the viral dynamics during 1–2 weeks after the initialization
of treatment.
Assuming no new infectious virions (VI ) but some noninfectious virions (VNI ) will still be pro-
duced, which means there is a perfect protease inhibitor treatment effect [13], the HIV dynamics
can be expressed as the following system of ODE:
dT ∗
dt = kVIT − δT ∗
dVI
dt = −cVI
dVNI
dt = NδT
∗ − cVNI
(4.3)
in which N is the number of new virions produced per infected cell during its life time. We can
obtain a close form solution to the system of ODE (4.3), assuming constant supply of target cell T
and quasi-steady state before treatment (dT ∗/dt = 0 and dV/dt = 0).
V (t) = V0 exp(−λt) + λV0λ−δ × [ λV0λ−δ{exp(−δt)− exp(−λt)} − δt exp(−λt)] (4.4)
where V (t) = VI(t) + VNI(t). Equation (4.4)was applied to more frequent measured HIV–1 RNA
data during the first week of treatment[13]. The estimated half-life of free virions and produc-
tively infected cells are about six hours and 1.6 days, respectively based on nonlinear least-squares
regression.
The ODE (4.3) was later further extended [19], to include a longer period of treatment that a
biphasical decay rate of plasma HIV-1 RNA was observed: the first phase, an initial rapid expo-
nential decline of nearly 2-logs (first phase), and the second phase a slower exponential decline. In
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this system, two more target cells are added: long-lived infected cells, macrophages (M), will be
infected into M∗ with a rate of kM , produce virions at rate of p and die with a rate of µM ; and
latently infected lymphocytes (L) will be produced by a rate constant fk and die at a rate of µL.
The HIV dynamics can be expressed as:
dT ∗
dt = kV T + αL− δT ∗
dL
dt = fkV T − µLL
dM∗
dt = kMVM − µMM∗
dV
dt = NδT
∗ + pM∗ − cV
(4.5)
where α is the rate of latent infected cells L becoming productively infected cells. With the similar
assumptions used for equation (4.4), a closed form solution to the system of ODE (4.5) can be
expressed as,
V (t) = V0[A exp(−δt) +B exp(−µLt) + C exp(−µM t) + (1 +A+B + C)] (4.6)
where A, B and C are functions of system parameters. 4.6 is too complicated to identify all pa-
rameters, even with additional peripheral blood mononuclear cells information. Therefore, some
parameters in 4.6 are assumed to be replaced by the values from previous studies. The first six
weeks since the treatment was used in equation (4.6) and the half-life of productively infected CD4
cells, long-lived infected cells and latently infected cells were estimated as 1.1 days, 14.1 days and
8.5 days, respectively.
Perfect treatment effect may not be a very reasonable assumption. Wu and Ding [20] proposed
a system of ODE including a protease inhibitor efficacy parameter of γ, 0 ≤ γ ≤ 1, while γ = 0
means the PI medications have no effect and γ = 1 means perfect effect. After some reasonable
simplification, the system of ODE is:
d
dtT
∗ = kVIT − δT ∗
d
dtVI = (1− γ)P − cVI
d
dtVNI = γP + P
∗ +NδT ∗ − cVNI
(4.7)
where P is the virus produced rate by productively infected cells, such as CD4 cell, P ∗ accounts
for virus produced from “mysterious” infected cells such as Langerhans cells and microglial cells,
or long-lived infected cells such as macrophages and latent infected cells, and k, T ∗, δ, VI , VNI , N
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and c have the same meaning as ODE (4.3). The system of ODE (4.7) gives a closed form solution,
V (t) = exp(P1 − λ1t) + exp(P2 − λ2t) + (P3 + P4t) exp(−ct) (4.8)
where V (t) = VI(t) + VNI(t), λ1 = δ is the first-phase viral decay rate that may represent the
minimum turnover rate of productively infected cells, such as CD4, λ2 is a possibly compound
clearance rate of long-lived and latently infected cells and the value depends on the infection rate
and destroyed rate by HIV virus. Because c has been estimated to be very rapid (less than 6 hours
of half life), it can be negligible compared with other terms. Thus, the equation (4.8) can be further
simplified as a two-exponential equation:
V (t) = exp(p1 − λ1t) + exp(p2 − λ2t) (4.9)
in which p1 and p2 are initial viral production rate from productively infected cells, long-lived and
latently infected cells, respectively. NLME modeling can be used in the estimation of the parameters
in equation (4.9).
Although the “cocktail” HAART treatment can suppress HIV in 60 to 90% of cases, 30 to 60%
of patients will end up as being considered treatment failure eventually because of the viral load
rebound [51]. However, the decay rates in all of the equations introduced are constant, which
means they cannot be applied to model rebound viral load values. Several extensions have been
developed in order to catch up viral load response that include rebound data, such as extending
from two exponential (4.8) by replacing the second constant decay rate with a time varying decay
rate function as [52]:
V (t) = exp(P1 − λ1t) + exp(P2 − λ2(t)t). (4.10)
Both HIV viral load and CD4 cell count are surrogate biomarkers of HIV progress status. CD4 cell
count is more often used as an endpoint for long follow-up trials or advanced patients population,
but for trials with short follow-up periods, viral load is often used as a primary endpoint to quantify
treatment effect, where CD4 cell count is viewed as a covariate to help predict virologic responses.
In viral load trajectory analysis, CD4 cell count is viewed as a time-varying covariate in λ2(t).
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4.2 Motivating data set
The data set that motivated this research is from an AIDS clinical trial study (ACTG398),which is
a randomized, double-blind, placebo-controlled, with an extension to more than 48 week study of
saquinavir, indinavir, or nelfinavir added as second protease inhibitor to the 4-drug class regimen in
patients with virologic failure defined by receiving saquinavir, nelfinavir, indinavir, or ritonavir[26].
This study consists of 481 HIV-1 infected patients. The plasma HIV-1 RNA (viral load) is repeatedly
quantified at weeks 0, 2, 4, 8, 16, and every 8 weeks until the last patient on study. The number
of viral load measurements for each individual varies from 2 to 13. Out of total 481 patients, 379
patients who had more than 2 measurements were included in data analysis. A log10 transformation
of viral load was used in the analysis in order to stabilize the variation of the measurement errors
and to speed up estimation algorithm. CD4 cell counts were also measured throughout study on
a similar scheme. 16.8% of 379 patients dropped out and never returned to the study, and 22% of
CD4 measures were missing at scheduled time points (i.e., intermittently missing measurements or
dropout patients may return to the study). The missing data or dropouts may be related to drug
resistance or other clinical problems.
4.3 Mixture components specification and covariate model for missing values
4.3.1 Mixture components specification
Based on discussion in Section 4.1, three useful approximations of ODE solution, which can be
used to capture viral load responses, have been proposed as follows.
y(t) = log10(e
p1−λ1t), (4.11)
y(t) = log10(e
p1−λ1t + ep2−λ2t), (4.12)
y(t) = log10(e
p1−λ1t + ep2−λ∗2t), (4.13)
where y(t) is the log10 scaled plasma HIV-1 RNA levels at time t, λ1 and λ2 are called the first- and
second-phase viral decay rates, which may represent the minimum turnover rate of productively
infected cells and that of latently or long-lived infected cells, respectively, λ∗2 is a time-varying
decay rate depending on CD4 cell count. The parameters p1 and p2 are macro-parameters; ep1 and
ep1+ep2 are the baseline viral load at time t = 0 in one- and two-compartment models, respectively.
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It is generally assumed that λ1 > λ2, which assures that the model is identifiable and is appropriate
for empirical studies [20]. Negative values of the decay rate λ∗2 may correspond to viral increase
and lead to viral rebound [20], suggesting that variation in the dynamic parameters may be partially
associated with time-varying covariates such as repeated CD4 cell counts.
Based on discussion above, we consider one- and two-compartment models with constant decay
rate(s) for trajectory classes 1 and 2 defined in Section 1.2, respectively, and a two-compartment
model with a time-varying decay rate in the second compartment for trajectory class 3. Thus, the
mean functions of K = 3 components in the mixture model are specified by
1. One-compartment model with a constant decay rate for class 1 trajectories
g1(A1,B1,β1i,Xi) = log10(e
β1i1−β1i2tij ), (4.14)
2. Two-compartment model with constant decay rates for class 2 trajectories
g2(A2,B2,β2i,Xi) = log10(e
β2i1−β2i2tij + eβ2i3−β2i4tij ), (4.15)
3. Two-compartment model with constant and time-varying decay rates for class 3 trajectories
g3(A3,B3,β3i,Xi) = log10(e
β3i1−β3i2tij + eβ3i3−β3i5tij ), (4.16)
Following the notation in Section (2.1), we can assign β, bi, Ak, Bk, and βki (k = 1, 2, 3), as
follow,
β = (β1, β2, β3, β4, β5, β6)
T , bi = (bi1, bi2, bi3, bi4, bi5, bi6)
T ,
β1i1 = β2i1 = β3i1 = β1 + bi1,
β1i2 = β2i2 = β3i2 = β2 + β5zi0 + bi2,
β2i3 = β3i3 = β3 + bi3,
β2i4 = β4 + bi4, β3i5 = β4 + β6z
∗
ij + bi4,
A1 = diag(1, 1, 0, 0, 0, 0),A2 = diag(1, 1, 1, 1, 1, 0),
A3 = diag(1, 1, 1, 1, 1, 1),B1 = diag(1, 1, 0, 0, 0, 0),
B2 = B3 = diag(1, 1, 1, 1, 0, 0),
Xi = (xi1, · · · ,xij , · · · ,xini),xij = (tij , zi0, z∗ij)T ,
(4.17)
where “diag” denotes a diagonal matrix with off-diagonal elements being 0, zi0 is CD4 baseline,
and z∗ij is true (but unobservable) value of CD4 at time tij defined below in Section 4.3.2. It is noted
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that (4.16) is a natural extension of (4.15) to employ a time-varying covariate CD4, z∗ij , to capture
viral rebound in class 3 trajectories.
4.3.2 Covariate models with missing and mismeasured data
Various covariate mixed-effect models were investigated in the literature [23, 24, 53, 54]. This sub-
section briefly discusses (CD4) covariate measurement error models with missing observations. Let
zij be the observed covariate values which may be missing because these covariate values may not
be observed at the yij measurement time tij , (i = 1, ..., n; j = 1, ..., ni). Let zi = (zmis,i, zobs,i),
where zmis,i and zobs,i are the collections of missing and observed components of zi, respectively.
Let ri = (ri1, ..., rini)
T be a vector of missing covariate indicator such that rij = 1 if zij is missing
and 0 otherwise.
In the presence of covariate measurement errors, we consider the following linear mixed-effects
(LME) model to quantify the covariate process.
zij = u
T
ijα+ v
T
ijai + ij(≡ z∗ij + ij),
i = (i1, ..., ini)
T iid∼ Nni(0, σ22Ini),
(4.18)
where z∗ij = u
T
ijα+ v
T
ijai can be viewed as the true (but unobservable) covariate value at time tij ,
uij = uij(tij) and vij = vij(tij) are l×1 design vectors,α = (α1, ..., αl)T and ai = (ai1, ..., ail)T
are unknown population (fixed-effects) and individual-specific (random-effects) parameter vectors,
respectively. The random-effects vector ai follows a multivariate normal distribution N(0,Σa),
where Σa is an unrestricted variance-covariance matrix.
To allow for nonignorable missing mechanism in covariate, we need to assume a missing data
model for the missing covariate mechanism. We consider following simple independent missing
data model.
f(r|η) =
n∏
i=1
f(ri|η) =
n∏
i=1
ni∏
j=1
[P (rij = 1|η)]rij [1− P (rij = 1|η)]1−rij , (4.19)
where logit[P (rij = 1|η)] = η0 + η1zij , and η = (η0, η1)T is a vector of unknown nuisance pa-
rameters. As we know, the nonignorable missing model (4.19) is not testable based on the observed
data, it is important to carry out sensitivity analysis based on different missing data models. For
example, we can consider the following alternative missing data models: logit[P (rij = 1|η)] =
η0 + η1zi,j−1 + η2zij or logit[P (rij = 1|η)] = η0 + η1zi,j + η2z2i,j . Similar to sensitivity analysis
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conducted by [55], the modeling results are robust against the missing (dropout) data models, we,
therefore, focus on the simpler missing data model (4.19) to avoid too many nuisance parameters.
We assume that the second viral decay rate in mean function (4.16) of component 3, β3i5, is
related to the true CD4 values rather than the observed but possibly mismeasured CD4 values. To
model the CD4 process, we consider empirical LME models and choose the best model (4.18) with
quadratic (l = 3) based on AIC/BIC model selection criteria as suggested by [24] and [23]. Thus,
we adopted the quadratic polynomial as the covariate model (4.18) with uij = vij = (1, tij , t2ij)
T
for the CD4 trajectory as follows:
zij = (α1 + ai1) + (α2 + ai2)tij + (α2 + ai2)t
2
ij + ij , (4.20)
where true CD4 value z∗ij = (α1 + ai1) + (α2 + ai2)tij + (α2 + ai2)t
2
ij , α = (α1, α2, α3)
T is a
population (fixed-effects) parameter vector, ai = (a1i, a2i, a3i)
T is an individual-specific (random-
effects) vector with distribution N(0,Σa), and i = (1, ..., ni)
T ∼ Nni(0, σ22Ini).
4.4 MCMC implementation
To carry out the Bayesian inference, we took weakly-informative prior distributions for the param-
eters in Models I, II and III. In particular, (i) fixed-effects were taken to be independent normal
distribution N(0, 100) for each element of the population parameter vectors β, α and η; (ii) we
assume a noninformative inverse Gamma prior distribution IG(0.01, 0.01), which has mean 1 and
variance 100, for variance parameters σ2 and σ22; (iii) the priors for the variance-covariance ma-
trices of the random-effects Σ and Σa were taken to be inverse Wishart distributions IW (Ω1, υ1)
and IW (Ω2, υ2), where the diagonal elements for diagonal variance matrix Ω1 and Ω2 were 0.01,
and υ1 = υ2 = 4; and (vi) finally, we set hyper-parameters of Dirichlet distribution in (2.10),
φ1 = φ2 = φ3 = 1, assuming individuals have equal probabilities of coming from any one of three
classes initially.
The MCMC sampler was implemented using WinBUGS software [42] interacted with a function
called bugs in a package R2WinBUGS of R. When the MCMC procedure was applied to the
actual clinical data, convergence of the generated samples was assessed using standard tools within
WinBUGS software such as trace plots and Gelman-Rubin (GR) diagnostics [43]. Figure 14 shows
the dynamic version of GR diagnostics based on Model I as obtained from the WinBUGS software
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for the representative parameters where the three curves are given: the middle and bottom curves
below the dashed horizontal line (indicated by the value one) represent the pooled posterior variance
(Vˆ ) and average within-sample variance (W ), respectively, and the top curve represents their ratio
(Rˆ). It is seen that Rˆ tends to 1, and Vˆ and W will stabilize as the number of iterations increase
indicating that the algorithm has approached convergence. Figures 15 and 16 show the trace plots
and the histograms of six representative parameters, β1–β6. When the horizontal line on each plot
of the trace plots is stabile we consider convergence reached. This line is the cumulative average
of the parameter estimate. The histograms show the distribution of each parameter and all look
normally distributed.
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Figure 14.: Gelman-Rubin (GR) diagnostic plot based on the NLME mixture model with three
Markov chains as obtained from the WinBUGS software for representative parameters.
With the convergence diagnostics observed, we proposed that, after an initial number of 50,000
burn-in iterations of three chains of length 100,000, every 50th MCMC sample was retained from
the next 50,000 for each chain. Thus, we obtained a total of 3,000 samples of targeted posterior
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Figure 15.: Traceplots of MCMC parameter samples (β1–β6).
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Figure 16.: Histograms of MCMC parameter samples (β1–β6).
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distributions of the unknown parameters for statistical inference.
4.5 Results
As mentioned above in Section 1.2, one of the primary objectives in this data analysis was to clus-
ter all individuals into 3 classes of viral load trajectories: (i) decrease rapidly and constantly in a
short-term period, (ii) decrease at the beginning and then maintain stable at a low level, and (iii)
decrease at the beginning, but rebound later. Based on the mixture modeling, we are able to obtain
a summary of class membership at both the population and individual levels. At population level,
the MCMC procedure yields samples from the posterior distribution of pi = (pi1, pi2, pi3)
T in (2.14),
the population proportion of individuals in each class. The estimates of population proportion and
95% equal-tail CIs of (pi1, pi2, pi3) are shown in Table 14. It can be seen that class 2 (decrease
and maintain stable) has the largest proportion, 47.86%, followed by class 3 (decrease and rebound
later) with proportion, 42.86%, and, then, class 1 (decrease all the time) with the lowest proportion,
9.28%. At individual level, the posterior probability of individual i belonging to the kth (k = 1, 2, 3)
class, pik = E[I(ci = k)], can be approximated by 1M
∑M
m=1 I(c
(m)
i = k), in which c
(m)
i is class
membership of individual i drawn from the posterior distribution (2.12) in themth MCMC iteration
(m = 1, ...,M ), whereM is total iteration number of posterior samples. Barplot shown in Figure 17
displays the probabilities for the 20 individuals. The probability corresponding to individual patient
who is classified as either viral load rebound or not may help physicians to refine treatment strategy
and to identify the reason of viral load rebound for such individual patient. Table 5 shows individ-
ual posterior probabilities for the six representative patients shown in Figure 3(a). The probabilities
shown in Table 15 and the classes of trajectories shown in Figure 3(a) are matched quite well. The
patients 31 and 105 belong to class 1 because their viral load decrease constantly in a early short-
term period, with probabilities 56% and 52%, respectively; the viral loads of the patients 29 and
132 decrease and then maintain stable, and thus, they belong to class 2, with probabilities 99% and
100%, respectively; and finally, the patients 33 and 99 are in class 3 (viral load rebound), with both
probabilities being 100%.
The estimated population parameters presented in Table 13 indicate that the first-phase decay rate,
and the second-phase decay rate without and with time-varying CD4 covariate may be approximated
by λˆ1 = 91.2 + 6.5z0, λˆ2 = 0.44 and λˆ∗2(t) = 0.44 + 39.6(−0.68 + 1.46t− 0.78t2), respectively,
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Table 13: Summary of the estimated posterior mean (PM) of population (fixed-effects), precision
parameters, and corresponding standard deviation (SD), lower limit (LCI ) and upper limit (UCI ) of
95% equal-tail credible interval (CI).
β1 β2 β3 β4 β5 β6 α1 α2 α3 σ
2 σ22
PM 10.3 91.2 6.5 5.9 0.44 39.6 -0.68 1.46 -0.78 0.33 1.22
LCI 10.1 81.8 0.52 5.7 -0.07 35.7 -0.76 1.14 -1.18 0.31 1.05
UCI 10.4 98.9 12.5 6.1 0.84 43.5 -0.58 1.77 -0.33 0.36 1.36
SD 0.08 4.85 3.01 0.16 0.29 2.08 0.05 0.17 0.21 0.01 0.09
Table 14: Summary of population proportion and 95% equal-tail credible interval (CI) for 3 trajec-
tory classes.
Class Proportion(pi) 95% CI
1 9.28 % (7.25, 11.64%)
2 47.86% (45.07, 50.75%)
3 42.86% (39.83, 45.56%)
Table 15: Individual posterior probabilities of belonging to 3 trajectory classes for six representa-
tive patients.
Class Patient ID pi1 pi2 pi3
1 31 57% 37 % 6 %
1 105 52% 41 % 7 %
2 29 0 % 99 % 1 %
2 132 0 % 100% 0 %
3 33 0 % 0 % 100%
3 99 0 % 0 % 100%
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Figure 17.: Posterior probabilities of belonging to 3 trajectory classes for 20 patients(from the 21st
to the 40th patient).
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where z0 is the baseline CD4 value. The population viral load processes, Vˆ , of 3 classes may be
approximated by Vˆ1(t) = exp
{
10.3− λˆ1t
}
, Vˆ2(t) = exp
{
10.3− λˆ1t
}
+ exp
{
5.9− λˆ2t
}
and
Vˆ3(t) = exp
{
10.3− λˆ1t
}
+ exp
{
5.9− λˆ∗2(t)t
}
. Since the first-phase viral decay rate, λ1, is
significantly associated with the baseline CD4 (due to significant estimate of β3) and the second-
phase viral decay rate λ∗2(t) in component 3 is significantly associated with the true (but unobserved)
CD4 values, this suggests that the viral load V (t) may be significantly associated with both the
baseline CD4 and the true CD4 values. This simple approximation considered here may provide a
rough guidance and point to further research even though the true association described above may
be more complicated.
4.5.1 The dependence of posterior probability on covariates
The finite mixture model in this article can be extended in most applications to model the probabili-
ties of class membership as a function of covariates. This could be accomplished by using a logistic
regression for the probability of belonging to class k with a reference to be the last class, K,
ln(pik/piK) = xTi γk, (k = 1, ...,K − 1) (4.21)
where pik is posterior class membership probability defined in (2.12), xi (u×1) is a vector of inter-
cept and other covariates for subject i, and γk = (γk1, ..., γku)
T , (k = 1, ...,K − 1), are unknown
parameter vectors. In practice, model (4.21) can be fitted for the mth iteration of MCMC procedure
based on class membership indicators c(m)i = (c
(m)
1 , ..., c
(m)
n )
T
and then we can make inference
for γk based on all estimated γ
(m)
k , (m = 1, ...,M), in which c
(m)
i is class membership indicator
vector in the mth MCMC iteration and M is the number of total iterations. In the context of HIV
dynamic example here, xi is a 4× 1 vector of intercept and other three dummy treatment variables
because there are four treatment groups, amprenavir, abacavir, efavirenz, and adefovir dipivoxil (see
Section 4.2 for details). Other covariates, such as gender and age, could be incorporated but none
of them are significant (results not shown). Unlike patients in class 3, those in classes 1 and 2 did
not have viral load rebound indicating a successful therapy so that class 1 and 2 are combined when
doing the logistic regression. The results of class membership logistic regression are summarized
in Table 16. The estimated γk can be interpreted, for example, that the odds of having viral load
rebound of patients in treatment 4 group, receiving adefovir dipivoxil, is exp(0.46) = 1.58 times
more than that in patients in in treatment 1 group, receiving amprenavir. Based on results, patients
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in treatment 1 group are most likely not to have viral load rebound, followed by treatment 3 and 2,
and patients in treatment 4 group are most likely to have viral load rebound.
Table 16: Estimated parameters in class membership indicator logistic regression(Treatment 4
group is reference).
Intercept Treatment 1 Treatment 2 Treatment 3
PM -0.31 0.46 0.09 0.25
LCI -0.65 0.10 -0.24 -0.041
UCI -0.011 0.84 0.47 0.59
SD 0.16 0.17 0.18 0.15
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Chapter 5
Discussion
For CD4 and viral load trajectories with population heterogeneity characteristic, we have developed
a Bayesian approach to finite mixture of NLME models that may be preferred over a single-class
NLME model in the sense that all individuals do not have to variate around a common mean trajec-
tory and can be clustered into several classes based the model. The proposed method may have a
significant impact on AIDS research because, in the presence of heterogeneity in response, appro-
priate statistical inference for CD4 trajectories and HIV dynamics is important for making reliable
clinical decisions. Besides, based on the multinomial logistic regression, we can make prediction
about the class membership one year later based on the available data for CD4 trajectories. Although
this topic is motivated by AIDS study, the basic concepts of the newly-developed mixture modeling
approach have generally broader applications. Thus, our proposed method can be readily applied in
other fields as long as the relevant technical specifications are met and longitudinal measurements
are assumed to come from two or more identifiable subclasses within a population. Based on the
class membership prediction, clinical physicians can change or modify the therapy strategy accord-
ingly. For example, physicians may want to change the type of the HAART if a patient is predicted
to be in the class 4 one year later.
One advantage of mixture modeling is its flexibility to handle longitudinal data with different
characteristics (heterogeneity) and the results support that a mixture model provides a better fit to
the data than a single class model[27]. Another advantage of mixture modeling is model-based
probabilistic clustering to obtain class membership probabilities. The probabilities of belonging to
any one of three classes can be obtained at both population and individual levels. This information
may help physicians refine general therapeutic strategy and develop individualized treatment.
Finite mixture models are widely used in social statistics literature, but called growth mixture
model (GMM) and latent curve model (LCM), which is a is a special type of GMM. A linear
mean function is usually applied for all latent classes, and EM algorithm is often used to make
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inference[27]. The proposed mixture model extended GMM in the sense that the mean function
can take a non-linear form. When the mixture model is extended to incorporate nonlinear mean
functions, the EM algorithm would become complex partially because the likelihood function does
not have a closed form anymore. In the E step of EM algorithm, we need to take an expectation of
the ”complete” likelihood function. Since the the ”complete” likelihood function does not have a
closed form, we must either approximate the integration in the likelihood, using Taylor enpension, or
evaluate the integration using Monte Carlo method. Both approaches involve intensive computation
and great efforts of statistical programming. We proposed a Bayesian inference method for mixture
models based on nonlinear mean functions, which provides not only estimates of model parameters
but also model-based probabilities of belonging to any one of K classes, simultaneously. Deviance
information criterion (DIC) is currently widely used to compare candidate models under Bayesian
framework. WinBUGS has a built-in function to calculate DIC, but it does not calculate DIC for
mixture models due to the complexity of mixture models. As shown in Section 2.2.5, DIC for
mixture model in this case is calculated in R. The program can be used to calculate DIC in other
mixture model applications.
A fundamental problem for “traditional” Bayesian mixture model analysis, in which each compo-
nent has the same family of densities but with different sets of parameters, is label switching due to
the non-identifiability of mixture components under symmetric priors [57, 58]. The so-called “label
switching” problem originated from the fact, using the Stepens’ notation [57], that the likelihood
L(θ,x) =
n∏
i=1
{pi1f(xi;φ1, η) + ...+ piKf(xi;φK , η)} ,
is the same for all permutations of θ. This problem arises in traditional mixture models in which each
component has the same form of density function, but with component-specific sets of parameters.
However, there is no label switching problem in our case based on our understanding, since each
component (k) has distinct mean function, gk(.), sharing the same set of parameters with different
dimensions of parameters for each component. With different mean functions with the same set of
parameters, the likelihood can be expressed as
L(θ,x) =
n∏
i=1
{pi1f1(xi; g1(θ)) + ...+ piKfK(xi; gK(θ))} .
Label switching problem does not happen because components correspond to different mean func-
tions gk, (j = 1, ...,K), which are known and pre-specified. Instead of specifying different mean
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functions for classes, alternatively, we can also specify an universal mean function for all classes
and let data themselves determine how many clusters there are and shapes of trajectories. In that
way the label switching problem may arise and we need to interpret the results differently.
Term “identifiability” means that for a model, any two distinct sets of parameters lead to different
data distribution [56], which in turn leads to different likelihood function. As Pauler and Laird [29]
pointed out, a finite mixture model is identifiable if each of component models is identifiable and
distinguishable from each other. Hennig [56] gave some examples in which each component linear
regression is identifiable but the whole mixture model is not identifiable. Based on our understand-
ing, this identifiability problem does not happen in a longitudinal trajectory analysis case, because
we know what outcomes are from the same subjects (In Henning’s case, the identifiability problem
happened because there are more than one combinations of means of y, see Section 2 Hennig’s
paper for details), and each component has its specific mean function.
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